Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology

Pharmacological Reviews

Volumn 45, Issue 1, 1993, Pages 87-146

  Roques, Bernard P ^a   Noble, Florence ^a   Daugé, Valérie ^a   Fournié Zaluski, Marie Claude ^a   Beaumont, Ann ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETORPHAN; ATRIAL NATRIURETIC FACTOR; BESTATIN; CANDOXATRILAT; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE; DNA; ENKEPHALIN; ENZYME INHIBITOR; KELATORPHAN; MEMBRANE METALLOENDOPEPTIDASE; METENKEPHALIN; MORPHINE; N (1 CARBOXY 2 PHENYLETHYL)PHENYLALANYL BETA ALANINE; N (1 CARBOXY 3 PHENYLPROPYL)PHENYLALANYLISOSERINE; N [2 BENZYL 3 [(HYDROXYAMINO)CARBONYL]PROPIONYL]PHENYLALANINE; NALOXONE; OPIATE; PHOSPHORAMIDON; RETROTHIORPHAN; THIORPHAN;

ANALGESIA; BEHAVIOR; DIARRHEA; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME SPECIFICITY; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; REVIEW; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; ANALGESICS; ANIMAL; CENTRAL NERVOUS SYSTEM; HUMAN; MOLECULAR SEQUENCE DATA; NEPRILYSIN;

EID: 0027475050     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (636)

1. ABASSI, Z. A., TATE, J. E., GOLOMB, E., AND KEISER, H. R.: Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 20: 89-95, 1992.
2. ABDELHAMID, E. E., AND TAKEMORI, A. E.: Characteristics of μ and δ opioid binding sites in striatal slices of morphine-tolerant and -dependent mice. Eur. J. Pharmacol. 198: 157-163, 1991.
3. ABURAYA, M., MINAMINO, N., KANGAWA, K., TANAKA, K., AND MATSU, H.: Distribution and molecular forms of brain natriuretic peptide in porcine heart and blood. Biochem. Biophys. Res. Commun. 165: 872-879, 1989.
4. ACQUAS, E., CARBONI, E., AND DI CHIARA, G.: Profound depression of mesolimbic dopamine release after morphine withdrawal in dependent rats. Eur. J. Pharmacol. 193: 133-134, 1991.
5. ACQUAS, E., AND DI CHIARA, G.: Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence. J. Neurochem. 58: 1620-1625, 1992.
6. AGHAJANIAN, G. K.: Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine. Nature (Lond.) 276: 186-188, 1978.
7. AKIL, H., MADDEN, J., PATRICK, R. L., AND BARCHAS, J. D.: Stress-induced increase in endogenous opiate peptides: concurrent analgesia and its partial reversal by naloxone. In Opiates and Endogenous Opioid Peptides, ed. by H. W. Kosterlitz, pp. 63-70, Elsevier, North-Holland, Amsterdam, The Netherlands, 1976a.
8. AKIL, H., MAYER, D. J., AND LIEBESKIND, J. C.: Antagonism of stimulation produced analgesia by naloxone, a narcotic antagonist. Science 191: 961-962, 1976b.
9. AKOEV, G. N., ILYINSKY, O. B., KOLOSOVA, L. I., TITOV, M. I., AND TROFIMOVA, O. G.: The effect of opioid peptides on the functional recovery of damaged neuronal structures. In Mechanoreceptors: development, structure and function, ed. by P. Hnik, T. Soukup, R. Vejsada, and J. Zelena, pp. 175-180, Plenum Press, New York, London, 1989.
10. 2]Met-enkephalin amide central effects after administration of an enkephalinase inhibitor. Eur. J. Pharmacol. 74: 261-262, 1981.
11. ALLARD, M., ZAJAC, J. M., AND SIMONNET, G.: Autoradiographic distribution of receptors to FLFQPQR amide, a morphine-modulating peptide, in rat central nervous system. Neuroscience 49: 101-116, 1992.
12. ALMENOFF, J., AND ORLOWSKI, M.: Biochemical and immunological properties of a membrane-bound brain metalloendopeptidase: comparison with thermolysin-like kidney neutral metalloendopeptidase. J. Neurochem. 42: 151-157, 1984.
13. ALMENOFF, J., WILK, S., AND ORLOWSKI, M.: Membrane bound pituitary metallopeptidase: apparent identity to enkephalinase. Biochem. Biophys. Res. Commun. 102: 206-214, 1981.
14. AL-RODHAN, N., CHIPKIN, R., AND YAKSH, T. L.: The antinociceptive effects of SCH 32615, a neutral endopeptidase (enkephalinase) inhibitor, microinjected into the periaqueductal, ventral medulla and amygdala. Brain Res. 520: 123-130, 1990.
15. ALTSTEIN, M., BLUMBERG, S., AND VOGEL, Z.: Phosphoryl-Leu-Phe: a potent inhibitor of the degradation of enkephalin by enkephalinase. Eur. J. Pharmacol. 76: 299-300, 1982.
16. ALTSTEIN, M., BACHER, E., VOGEL, Z., AND BLUMBERG, S.: Protection of enkephalins from enzymatic degradation utilizing selective metal-chelating inhibitors. Eur. J. Pharmacol. 91: 353-361, 1983.
17. AOKI, K., KAJIWARA, M., AND OKA, T.: The role of bestatin sensitive aminopeptidase, angiotensin converting enzyme and thiorphan sensitive "enkephalinase" in the potency of enkephalins in the guinea-pig ileum. Jpn. J. Pharmacol. 36: 59-65, 1984.
18. APPELBOOM, T., MAERTELAER, V. D., PREZ, E. D., HAUZEUR, J., AND DESCHODT-LANCKMAN, M.: Enkephalinase: a physiologic neuroimmunomodulator detected in the synovial fluid. Arthritis Rheum. 34: 1048-1051, 1991.
19. ARAI, H., NAKAO, K., SAITO, Y., SUGAWARA, A., YAMADA, T., ITOH, H., SHIONO, S., MUKOYAMA, M., OHKUBO, H., NAKANISHI, S., AND IMURA, I.: Augmented expression of atrial natriuretic polypeptide gene in ventricles of spontaneously hypertensive rats (SHR) and SHR-stoke prone. Circ. Res. 62: 926-930, 1988.
20. AROCK, M., GROS, C., DEVILLIER, P., GUILLOSSON, J. J., AND SCHWARTZ, J. C.: Characterization of enkephalinase (EC 3.4.24.11) activity on various leukemic cells expressing the common acute lymphocytic leukemia antigen. FEBS Lett. 248: 123-126, 1989.
21. ARREGUI, A., EMSON, P. C., AND SPOKES, E. G.: Angiotensin converting enzyme in substantia nigra: reduction of activity in Huntington's disease and after intra-striatal kainic acid in rats. Eur. J. Pharmacol. 52: 121-124, 1978.
22. AUBRY, M., BERTELOT, A., BEAUMONT, A., ROQUES, B. P., AND CRINE, P.: The use of a monoclonal antibody for the high yield purification of kidney "enkephalinase" solubilized in octylglucoside. Biochem. Cell Biol. 65: 398-404, 1987.
23. BAAMONDE, A., DAUGÉ, V., GACEL, G., AND ROQUES, B. P.: Systemic administration of (Tyr-D-Ser(O-Tert-Butyl)-Gly-Phe-Leu-Thr(O-Tert-Butyl), a highly selective delta opioid agonist, induces mu receptor-mediated analgesia in mice. J. Pharmacol. Exp. Ther. 257: 767-773, 1991.
24. 1 dopamine receptor stimulation. Eur. J. Pharmacol. 216: 157-166, 1992.
25. BABER, N. S., DOURISH, C. T., AND HILL, D. R.: The role of CCK, caerulein, and CCK antagonists in nociception. Pain 39: 307-328, 1989.
26. BACK, S. A., AND GORENSTEIN, C.: Localization of neutral metalloendopeptidase 24-11 (enkephalinase) activity in rat brain. Fed. Proc. 45: 389, 1986.
27. BACK, S. A., AND GORENSTEIN, C.: Histochemical visualization of neutral endopeptidase-24.11 (enkephalinase) activity in rat brain: cellular localization and codistribution with enkephalins in the globus pallidus. J. Neurosci. 9: 4439-4455, 1989.
28. BADO, A., CHICAU-CHOVET, M., APPIA, F., DUBRASQUET, M., LECOMTE, J. M., AND ROZE, C.: Acetorphan, an enkephalinase inhibitor, decreases gastric secretion in cats. Peptides 8: 89-93, 1987.
29. BADO, A., ROZE, C., LEWIN, M. J. M., AND DUBRASQUET, M.: Endogenous opioid peptides in the control of food intake in cats. Peptides 10: 967-971, 1989.
30. BARCHAS, J. D., SULLIVAN, S., AKIL, H., BOARDER, M., WEBER, E., AND HEWLETT, W. C.: Studies related to the metabolic processing of endogenous opioids. Psychopharmacol. Bull. 17: 70-78, 1981.
31. BARNES, K., AND KENNY, A. J.: Endopeptidase 24-11 in the adenohypophysis of the pig is localized in the gonadotrophic cells. Peptides 9: 55-63, 1988.
32. BARNES, K., TURNER, A. J., AND KENNY, A. J.: Electron microscopic immunocytochemistry of pig brain shows that endopeptidase-24.11 is localized in neuronal membranes. Neurosci. Lett. 94: 64-69, 1988.
33. BARNES, K., TURNER, A. J., AND KENNY, A. J.: Membrane localization of endopeptidase-24.11 and peptidyl dipeptidase A (angiotensin converting enzyme) in the pig brain: a study using subcellular fractionation and electron microscopic immunocytochemistry. J. Neurochem. 58: 2088-2096, 1992.
34. BATEMAN, R. C., JR., JACKSON, D., SLAUGHTER, C. A., UNNITHAN, S., CHAI, Y. G., MOOMAW, C., AND HERSH, L. B.: Identification of the active site origin in rat neutral endopeptidase 24.11 (enkephalinase) as Arg 102 and analysis of a glutamine 102 mutant. J. Biol. Chem. 264: 6151-6157, 1989.
35. BATEMAN, R. C., YOUNG, A. E., SLAUGHTER, C., AND HERSH, L. B.: N-bromoacetyl-D-leucylglycine: an affinity label for neutral endopeptidase 24.11. J. Biol. Chem. 265: 8365-8368, 1990.
36. BAUMER, P., DANQUECHIN-DORVAL, E. D., BERTRAND, J., VETEL, J. M., SCHWARTZ, J. C., AND LECOMTE, J. M.: Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea. Gut 33: 753-758, 1992.
37. BEAN, A. J., AND VAUGHT, J. L.: Physical dependence produced by chronic intracerebroventricular infusion of [D-Arg]kyotorphin or thiorphan to rats. Eur. J. Pharmacol. 105: 333-337, 1984.
38. BEAUMONT, A., AND ROQUES, B. P.: Presence of a histidine at the active site of the neutral endopeptidase-24.11. Biochem. Biophys. Res. Commun. 139: 733-739, 1986.
39. 14C]azidothiorphan. Mol. Pharmacol. 32: 594-599, 1987.
40. BEAUMONT, A., BROUET, J. C., AND ROQUES, B. P.: Neutral endopeptidase 24.11 and angiotensin converting enzyme like activity in CALLA positive and CALLA negative lymphocytes. Biochem. Biophys. Res. Commun. 160: 1323-1329, 1989.
41. 747 are involved in substrate binding to neutral endopeptidase-24.11. J. Biol. Chem. 266: 214-220, 1991.
42. BEAUMONT, A., BARBE, B., LE MOUAL, H., BOILEAU, G., CHINE, P., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Charge polarity reversal reverses the specificity of neutral endopeptidase-24.11. J. Biol. Chem. 267: 2138-2141, 1992.
43. BEITNER, D. B., DUMAN, R. S., AND NESTLER, E. J.: A novel action of morphine in the rat locus coeruleus: persistent decrease in adenylate cyclase. Mol. Pharmacol. 35: 559-564, 1989.
44. BEITNER-JOHNSON, D., AND NESTLER, E. J.: Morphine and cocaine exert common chronic actions on tyrosine hydroxylase in dopaminergic brain reward regions. J. Neurochem. 57: 344-347, 1991.
45. BELLUZI, J. D., GRANT, N., GARSKY, V., SARANTAKIS, D., WISE, C. D., AND STEIN, D.: Analgesia induced in vivo by central administration of enkephalin in rat. Nature (Lond.) 260: 625-626, 1976.
46. BENCHETRIT, T., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Relationship between the inhibitory potencies of thiorphan and retrothiorphan enantiomers on thermolysin and neutral endopeptides 24.11 and their interactions with the thermolysin active site by computer modelling. Biochem. Biophys. Res. Commun. 147: 1034-1040, 1987.
47. BENCHETRIT, T., BISSERY, V., MORNON, J. P., DEVAULT, A., CRINE, P., AND ROQUES, B. P.: Primary structure homologies between two Zn-metallopeptidases, the neutral endopeptidase 24.11 "enkephalinase" and the thermolysin through clustering. Biochemistry 27: 592-597, 1988.
48. BEN NATAN, L., CHAILLET, P., LECOMTE, J. M., MARCAIS, H., UCHIDA, G., AND COSTENTIN, J.: Involvement of endogenous enkephalins in the mouse "behavioral despair" test. Eur. J. Pharmacol. 97: 301-304, 1984.
49. BENOLIEL, J. J., BOURGOIN, S., MAUBORGNE, A., LEGRAND, J. C., HAMON, M., AND CESSELIN, F.: Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by κ receptor stimulation. Neurosci. Lett. 124: 204-207, 1991.
50. BENOLIEL, J. J., MAUBORGNE, A., BOURGOIN, S., LEGRAND, J. C., HAMON, M., AND CESSELIN, F.: Opioid control of the in vitro release of cholecystokinin-like material from the rat substantia nigra. J. Neurochem. 58: 916-922, 1992.
51. 7 degradation by rat striatal synaptosomal membranes. Neurochem. Int. 4: 389-396, 1982.
52. BENUCK, M., AND MARKS, N.: Co-identity of brain angiotensin converting enzyme with a membrane bound dipeptide carboxypeptidase inactivating Metenkephalin. Biochem. Biophys. Res. Commun. 88: 215-221, 1979.
53. BERGMANN, J. F., CHAUSSADE, S., COUTURIER, D., BAUMER, P., SCHWARTZ, J. C., AND LECOMTE, J. M.: Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on oro-caecal and colonic transit times in healthy volunteers. Aliment. Pharmacol. Ther. 6: 305-313, 1992.
54. BESSE, D., LOMBARD, M. C., ZAJAC, J. M., AND ROQUES, B. P.: Pre- and postsynaptic distribution of μ, δ and κ opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res. 521: 15-22, 1990.
55. BESSON, J. M., AND CHAOUCH, A.: Peripheral and spinal mechanisms of nociception. Physiol. Rev. 64: 67-186, 1987.
56. BINDER, H. J., LAURENSON, J. P., AND DOBBINS, J. W.: Role of opiate receptors in regulation of enkephalin stimulation of active sodium and chloride absorption. Am. J. Physiol. 247: G432-G436, 1984
57. BLUM, K., TRACHTENBERG, M. C., ELLIOT, C. E., DINGLER, M. L., SEXTON, R. L., SAMUALS, A. I., AND CATALDIE, L.: Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double blind placebo-controlled study of the nutritional adjunct SAAVE. Alcohol 5: 481-493, 1989.
58. 1-opiate receptors in supraspinal opiate analgesia: a microinjection study. Brain Res. 447: 25-34, 1988.
59. BODNAR, R., PAUL, D., AND PASTERNAK, G. W.: Synergistic analgesic interactions between the periaqueductal gray and the locus coeruleus. Brain Res. 558: 224-230, 1991.
60. BORSON, D. B., AND GRUENERT, D. C.: Glucocorticoids induce neutral endopeptidase in transformed human tracheal epithelial cells. Am. J. Physiol. 260: L83-L89, 1991.
61. BOSCH, F. X., GARTEN, W., KLENK, H. D., AND ROTT, R.: Proteolytic cleavage of influenza virus hemoglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of ovian influenza viruses. Virology 113: 725-735, 1981.
62. BOUBOUTOU, R., WAKSMAN, G., DEVIN, J., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Bidentate peptides: highly potent new inhibitors of enkephalin degrading enzymes. Life Sci. 35: 1023-1030, 1984.
63. BOUDINOT, E., DENAVIT-SAUBIÉ, M., FOURNIÉ-ZALUSKI, M. C., MORIN-SURUN, M. P., AND ROQUES, B. P.: Respiratory consequences in cats and rats of inhibition of enkephalin-degrading enzymes by kelatorphan. J. Physiol. 406: 169P, 1988.
64. BOURGOIN, S., LE BARS, D., ARTAUD, F., CLOT, A. M., BOUBOUTOU, R., FOURNIÉ-ZALUSKI, M. C., ROQUES, B. P., HAMON, M., AND CESSELIN, F.: Effects of kelatorphan and other peptidase inhibitors on the in vitro and in vivo release of met-enkephalin-like material from the rat spinal cord. J. Pharmacol. Exp. Ther. 238: 360-366, 1986.
65. BOURGOIN, S., LE BARS, D., CLOT, A. M., HAMON, M., AND CESSELIN, F.: Spontaneous and evoked release of met-enkephalin-like material from the spinal cord of arthritic rats in vivo. Pain 32: 107-114, 1988.
66. BOURGOIN, S., LE BARS, D., CLOT, A. M., HAMON, M., AND CESSELIN, F.: Subcutaneous formalin induces a segmental release of Met-enkephalin-like material from the rat spinal cord. Pain 41: 323-329, 1990.
67. BOUSSELMAME, R., EUSTACHE, M., MICHAEL-TITUS, A., AND COSTENTIN, J.: Chronic inhibition of enkephalinase induces changes in the antinociceptive and locomotor effects of the enkephalinase inhibitor acetorphan in rats. Neuropharmacology 30: 865-870, 1991a.
68. BOUSSELMAME, R., MICHAEL-TITUS, A., AND COSTENTIN, J.: Desensitization of μ-opioid receptors does not modify the analgesia induced by an enkephalinase inhibitor. Eur. J. Pharmacol. 203: 295-297, 1991b.
69. BOWES, M. A., AND KENNY, A. J.: Endopeptidase-24.11 in pig lymph nodes: purification and immunocytochemical localization in reticular cells. Biochem. J. 236: 801-810, 1986.
70. BOZARTH, M. A.: Neural basis of psychomotor stimulant and opiate reward: evidence suggesting the involvement of a common dopaminergic system. Behav. Brain Res. 22: 107-116, 1986.
71. BOZARTH, M. A., AND WISE, R. A.: Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 225: 516-517, 1984.
72. BRALET, J., MOSSIAT, C., GROS, C., AND SCHWARTZ, J. C.: Thiorphan-induced natriuresis in volume-expanded rats: roles of endogenous atrial natriuretic factor and kinins. J. Pharmacol. Exp. Ther. 258: 807-811, 1991.
73. BRAUN, M. P., MARTIN, P. J., LEDBETTER, J. A., AND HANSEN, J. A.: Granulocytes and cultured human fibroblasts express common acute lymphoblastic leukemia-associated antigens. Blood 61: 718-725, 1984.
74. BRUSSAARD, A. B., KITS, K. S., TER MAAT, A., MULDER, A. H., AND SCHOFFELMEER, A. N. M.: Peripheral injection of DNS-RFa, a FMRFa agonist, suppresses morphine-induced analgesia in rats. Peptides 10: 735-739, 1989.
75. BUCHSBAUM, M. S., DAVIS, G. C., AND BUNNEY, W. E.: Naloxone alters pain perception and somatosensory evoked potentials in normal subjects. Nature (Lond.) 270: 620-622, 1977.
76. BUCKETT, W. R.: The actions of enkephalins are not modified by the "kininase II" inhibitor captopril. Eur. J. Pharmacol. 57: 267-271, 1979.
77. BURLEY, S. K., DAVID, P. R., SWEET, R. M., TAYLOR, A., AND LIPSCOMB, W. N.: Structure determination and refinement of bovine lens leucine aminopeptidase and its complex with bestatin. J. Mol. Biol. 224: 113-140, 1992.
78. BURNETT, J. C., KAO, P. C., Hu, D. C., HESER, D. W., HEUBLEIN, D., GRANGER, J. P., OPGENORTH, T. J., AND REEDER, G. S.: Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231: 1145-1147, 1986.
79. BURNIER, M., GRANSLMAYER, M., PERRET, F., PORCHET, M., KOSOGLOU, T., GOULD, A., NUSSBERGER, J., WAEBER, B., AND BRUNNER, H. R.: Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers. Clin. Pharmacol. Ther. 50: 181-191, 1991.
80. BUTCHER, S. P., VARRO, A., KELLY, J. S., AND DOCKRAY, G. J.: In vivo studies on the enhancement of cholecystokinin release in the rat striatum by dopamine depletion. Brain Res. 505: 119-122, 1989.
81. BUTLEN, D. M., MITSAOUI, M. M., AND MOREL, F.: ANF receptor along the rat and rabbit nephrons 125-I α rat ANP binding in microdissected glomeruli and tubules. Eur. J. Physiol. 408: 356-365, 1987.
82. CADOR, M., TAYLOR, J. R., AND ROBBINS, T. W.: Potentiation of the effects of reward-related stimuli by dopaminergic-dependent mechanisms in the nucleus accumbens. Psychopharmacology 104: 377-385, 1991.
83. CALENCO-CHOUKROUN, G., DAUGÉ, V., GACEL, G., FÉGER, J., AND ROQUES, B. P.: Opioid δ agonists and endogenous enkephalins induce different emotional reactivity than μ agonists after injection in the rat ventral tegmental area. Psychopharmacology 103: 493-502, 1991a.
84. CALENCO-CHOUKROUN, G., DAUGÉ, V., GACEL, G., AND ROQUES, B. P.: Lesion of dopamine mesolimbic neurons blocks behavioral effects induced by the endogenous enkephalins but not by a μ-opioid receptor agonist. Eur. J. Pharmacol. 209: 267-271, 1991b.
85. CARENZI, A., FRIGENI, V., AND DELLA-BELLA, D.: Strong analgesic activity of Leu-enkephalin after inhibition of brain aminopeptidase: a pharmacological study. In Advances in Endogenous and Exogenous Opioids, Proceedings of the International Narcotic Research Conference, ed. by H. Takagi and E. F. Simon, pp. 267-269, Kyoto, Japan, 1981.
86. CARENZI, A., CASACCI, F., MORPURGO, E., AND DELLA-BELLA, D.: Bestatin: a selective and potent inhibitor of enkephalin aminopeptidase. Adv. Biosci. 44: 121-126, 1983a.
87. CARENZI, A., FRIGENI, V., REGGIANI, A., AND DELLA-BELLA, D.: Effect of inhibition of neuropeptidases on the pain threshold of mice and rats. Neuropharmacology 22: 1315-1319, 1983b.
88. CASEY, M. L., SMITH, J. W., NAGAI, K., HERSH, L. B., AND MACDONALD, P. C.: Progesterone-regulated cyclic modulation of membrane metalloendopeptidase (enkephalinase) in human endometrium. J. Biol. Chem. 266: 23041-23047, 1991.
89. CAUDLE, R. M., WAGNER, J. J., AND CHAVKIN, C.: Endogenous opioids released from perforant path modulate norepinephrine release and IPSP amplitudes in guinea-pig CA3 pyramidal cells, J. Pharmacol. Exp. Ther. 258: 18-26, 1991.
90. CAVERO, P. G., MARGULIES, K. B., WINAVER, J., SEYMOUR, A. A., DELANEY, N. G., AND BURNETT, J. C.: Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation 82: 196-201, 1990.
91. CESSELIN, F., SOUBRIÉ, P., BOURGOIN, S., ARTAUD, F., REISINE, T. D., MICHELOT, R., GLOWINSKI, J., AND HAMON, M.: In vivo release of Met-enkephalin in the cat brain. Neuroscience 6: 301-308, 1981.
92. CESSELIN, F., OUVERAS, J. L., BOURGOIN, S., SIERRALTA, F., MICHELOT, R., BESSON, J. M., AND HAMON, M.: Increased levels of Met-enkephalin like material in the CSF of anesthetized cats after tooth pulp stimulation. Brain Res. 237: 325-338, 1982.
93. CESSELIN, F., BOURGOIN, S., CLOT, A. M., HAMON, M., AND LE BARS, D.: Segmental release of Met-enkephalin-like material from the spinal cord of rats, elicited by noxious thermal stimuli. Brain Res. 484: 71-77, 1989.
94. CHABARDES, D., MONTEGUT, M., MITSAOUI, M., BUTLEN, D., AND MOREL, F.: ANP effect on cyclic GMP and cyclic AMP contents in microdissected glomeruli and segment of the rat and rabbit nephrons. Eur. J. Physiol. 408: 366-372, 1987.
95. CHABRIER, P. E., ROUBERT, P., LONCHAMPT, M. O., PLAS, P., AND BRAQUET, P.: Receptor regulation of atrial natriuretic factor. Blood Vessels 27: 153-161, 1990.
96. CHAILLET, P., MARCAIS-COLLADO, H., AND COSTENTIN, J.: Catatonic or hypotonic immobility induced in mice by intracerebroventricular injection of mu and kappa opioid receptor agonists as well as enkephalins or inhibitors of their degradation. Life Sci. 33: 2105-2111, 1983a.
97. CHAILLET, P., MARCAIS-COLLADO, H., COSTENTIN, J., YI, C. C., DE LA BAUME, S., AND SCHWARTZ, J. C.: Inhibition of enkephalin metabolism by, and antinociception activity of, bestatin, an aminopeptidase inhibitor. Eur. J. Pharmacol. 86: 329-336, 1983b.
98. CHAILLET, P., COULAUD, A., ZAJAC, J. M., FOURNIÉ-ZALUSKI, M. C., COSTENTIN, J., AND ROQUES, B. P.: The mu rather than the delta subtype of opioid receptors appears to be involved in enkephalin induced analgesia. Eur. J. Pharmacol. 101: 83-90, 1984.
99. CHAN, W. W. C.: L-Leucinethiol, a potent inhibitor of leucine aminopeptidase. Biochem. Biophys. Res. Commun. 116: 297-302, 1983.
100. CHANG, K. J., CUATRECASAS, P., WEI, E. T., AND CHANG, J. K.: Analgesic activity of intracerebroventricular administration of morphiceptin and beta-casomorphins: correlation with morphine (mu) receptor binding affinity. Life Sci. 30: 1547-1551, 1982.
101. CHANG, M. S., LOWE, D. G., LEWIS, M., HELLMISS, R., CHEN, E., AND GOEDDEL, D.: Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclase. Nature (Lond.) 341: 68-72, 1989.
102. CHAPMAN, C. R., AND BENEDETTI, C.: Analgesia following transcutaneous electrical stimulation and its partial reversal by a narcotic antagonist. Life Sci. 21: 1645-1648, 1977.
103. CHAUSSADE, S., HAMM, R., LECOMTE, J. M., COUTURIER, D., AND GUERRE, J.: Effects of an enkephalinase inhibitor on esophageal motility in man. Gastroenterol. Clin. Biol. 12: 793-796, 1988.
104. CHECLER, F.: Peptidases and neuropeptide-inactivating mechanisms in the circulation and in the gastrointestinal tract. In Neuropeptide Function in the Gastrointestinal Tract, ed. by E. E. Daniel, pp. 274-307, CRC Press, Boston, MA, 1991.
105. CHECLER, F., VINCENT, J. P., AND KITABGI, P.: Degradation of neurotensin by rat brain synaptic membranes: involvement of a thermolysin like metalloendopeptidase (enkephalinase), angiotensin converting enzyme, and other unidentified peptidases. J. Neurochem. 41: 375-384, 1983.
106. CHÉROT, P., FOURNIÉ-ZALUSKI, M. C., AND LAVAL, J.: Purification and characterization of an enkephalin-degrading dipeptidyl aminopeptidase from porcine brain. Biochemistry 25: 8184-8191, 1986a.
107. CHÉROT, P., DEVIN, J., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Enkephalin degrading dipeptidylaminopeptidase: characterization of the active site and selective inhibition. Mol. Pharmacol. 30: 338-344, 1986b.
108. CHICAU-CHOVET, M., DUBRASQUET, M., CHARIOT, J., TSOCAS, A., LECOMTE, J. M., AND ROZE, C.: Thiorphan and acetorphan inhibit gastric secretion by a central non-opioid mechanism in the rat. Eur. J. Pharmacol. 154: 247-254, 1988.
109. CHILDERS, S. R.: Opioid receptor-coupled second messenger systems. Life Sci. 48: 1991-2003, 1991.
110. CHINKERS, M., GARBERS, D. L., CHANG, M. S., LOWE, D. G., CHIN, H., GOEDDEL, D. V., AND SCHULTZ, S.: A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature (Lond.) 338: 78-83, 1989.
111. CHIPKIN, R. E.: Inhibitors of enkephalinase: the next generation of analgesics. Drugs Future 11: 593-606, 1986.
112. CHIPKIN, R. E., IORIO, L. C., BARNETT, A., BERGER, J., AND BILLARD, W.: In vitro and in vivo effects of thiorphan: an inhibitor of enkephalinase A. In Regulatory Peptides: From Molecular Biology to Function, ed. by E. Costa and M. Trabucchi, pp. 235-241, Raven Press, New York, 1982a.
113. 2] enkephalinamide analgesia in rats by thiorphan. Eur. J. Pharmacol. 83: 283-288, 1982b.
114. CHIPKIN, R. E., LATRANYI, M. Z., AND IORIO, L. C.: Potentiation of stress-induced analgesia (SIA) by thiorphan and its block by naloxone. Life Sci. 31: 1189-1192, 1982c.
115. CHIPKIN, R. E., BERGER, J. G., BILLARD, W., IORIO, L. C., CHAPMAN, R., AND BARNETT, A.: Pharmacology of SCH34826, an orally active enkephalinase inhibitor analgesic. J. Pharmacol. Exp. Ther. 245: 829-838, 1988.
116. CHIPKIN, R. E., AND COFFIN, V. L.: Analgesic and acute central nervous system side effects of the intravenously administered enkephalinase inhibitor SCH 32615. Pharmacol. Biochem. Behav. 38: 21-27, 1991.
117. CHRISTIE, M. J., WILLIAMS, J. T., AND NORTH, R. A.: Cellular mechanisms of opioid tolerance: studies in single brain neurons. Mol. Pharmacol. 32: 633-638, 1987.
118. CODY, R. J., ATLAS, S. A., LARAGH, J. H., KUBO, H., COVIT, A. B., RYMAN, K. S., SHAKNOVICH, A., PONDOLFINO, K., CLARK, M., CAMARGO, J. F., SCARBOROUGH, R. M., AND LEWICKI, J. A.: Atrial natriuretic factor in normal subjects and heart failure patients. J. Clin. Invest. 78: 1362-1374, 1986.
119. COHEN, M. L., AND KURZ, K. D.: Angiotensin-converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J. Pharmacol. Exp. Ther. 220: 63-69, 1982.
120. COLLIN, E., MAUBORGNE, A., BOURGOIN, S., CHANTREL, D., HAMON, M., AND CESSELIN, F.: In vivo tonic inhibition of spinal substance P (-like material) release by endogenous opioid(s) acting at delta receptors. Neuroscience 44: 725-731, 1991.
121. CONNELLY, J. C., SKIDGEL, R. A., SCHULZ, W. W., JOHNSON, A. R., AND ERDOS, E. G.: Neutral endopeptidase 24-11 in human neutrophil: cleavage of chemotactic peptide. Proc. Natl. Acad. Sci. USA 82: 8737-8741, 1985.
122. COQUEREL, A., DUBUC, I., MENARD, J. F., KITABGI, P., AND COSTENTIN, J.: Naloxone-insensitive potentiation of neurotensin hypothermic effect by the enkephalinase inhibitor thiorphan. Brain Res. 398: 386-389, 1986.
123. CORVOL, P., AND MENARD, J.: Renin inhibition: immunological procedures and renin inhibitors peptides. Kidney Int. 34: 580-585, 1988.
124. COSTENTIN, J., VLAICULESCU, A., CHAILLET, P., BEN NATAN, L., AVEAUX, D., AND SCHWARTZ, J. C.: Dissociated effects of inhibitors of enkephalin metabolizing peptidases or naloxone on various nociceptive responses. Eur. J. Pharmacol. 123: 37-44, 1986.
125. 5]enkephalin in the globus pallidus. Proc. Natl. Acad. Sci. USA 85: 7028-7032, 1988.
126. COUPAR, I. M.: Opioid action on the intestine: the importance of the intestinal mucosa. Life Sci. 41: 917-925, 1987.
127. COX, B. M.: Molecular and cellular mechanisms in opioid tolerance. In Towards a New Pharmacotherapy of Pain, ed. by A. I. Basbaum and J. M. Besson, pp. 137-156, J. Wiley & Sons Ltd., New York, 1991.
128. CRAVES, F. B., LAW, P. Y., HUNT, C. A., AND LOH, H. H.: The metabolic disposition of radiolabeled enkephalins in vitro and in situ. J. Pharmacol. Exp. Ther. 206: 492-506, 1978.
129. D'ADAMIO, L., SHIPP, M. A., MASTELLER, E. L., AND REINHERZ, E. I.: Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5′ untranslated regions. Proc. Natl. Acad. Sci. USA 86: 7103-7107, 1989.
130. DANIELSEN, E. M., COWELL, G. M., NOREN, O., AND SJOSTROM, H.: Biosynthesis. In Mammalian Ectoenzymes, ed. by A. J. Kenny and A. J. Turner, pp. 47-85, Elsevier, Amsterdam, The Netherlands, 1987.
131. DAUGÉ, V., PETIT, F., ROSSIGNOL, P., AND ROQUES, B. P.: Use of μ and δ opioid peptides of various selectivity gives further evidence for specific involvement of μ opioid receptors in supraspinal analgesia (tail flick test). Eur. J. Pharmacol. 141: 171-178, 1987.
132. DAUGÉ, V., ROSSIGNOL, P., AND ROQUES, B. P.: Comparison of the behavioural effects induced by administration in rat nucleus accumbens or nucleus caudatus of selective μ and δ opioid peptides or kelatorphan, an inhibitor of enkephalin-degrading enzymes. Psychopharmacology 96: 343-352, 1988.
133. DAUGÉ, V., ROSSIGNOL, P., AND ROQUES, B. P.: Blockade of dopamine receptors reverses the behavioral effects of endogenous enkephalins in the nucleus caudatus but not in the nucleus accumbens: involvement of δ and μ opioid receptors. Psychopharmacology 99: 168-175, 1989.
134. DAUGÉ, V., KALIVAS, P. W., DUFFY, T., AND ROQUES, B. P.: Effects of inhibiting enkephalin catabolism in the VTA on motor activity and extracellular dopamine. Brain Res., 599: 209-216, 1992.
135. DAVIS, K. R., HERNANDEZ, D. E., AND WOLFENDEN, R.: Leucinal inhibits brain aminopeptidase activity and potentiates analgesia induced by Leu-enkephalin. Pharmacol. Biochem. Behav. 19: 791-794, 1983.
136. DAVIS, H. R., MCGREGOR, D. G., Hoos, L., MULLINS, D. E., AND SYBERTZ, E. J.: Atrial natriuretic factor and the neutral endopeptidase inhibitor SCH 42495 prevent myointimal proliferation after vascular injury. Circulation 86 (Suppl. 1): I-220, 1992.
137. DE BOLD, A. J.: Atrial natriuretic factor: a hormone produced by heart. Science 230: 767-770, 1985.
138. DE BOLD, A. J., BORENSTEIN, H. B., VERESS, A. T., AND SONNENBIRY, H.: A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci. 28: 89-94, 1981.
139. DE FELIPE, M. D. C., DE CEBALLOS, M. L., GIL, C., AND FUENTES, J. A.: Chronic antidepressant treatment increases enkephalin levels in N. accumbens and striatum of the rat. Eur. J. Pharmacol. 112: 119-122, 1985.
140. DE FELIPE, M. D. C., JIMENEZ, I., CASTRO, A., AND FUENTES, J. A.: Antidepressant action of imipramine and iprindole in mice is enhanced by inhibitors of enkephalin-degrading peptidases. Eur. J. Pharmacol. 159: 175-180, 1989.
141. DELAY-GOYET, P., ZAJAC, J.-M., JAVOY-AGID, F., AGID, Y., AND ROQUES, B. P.: Regional distribution of μ, δ and κ opioid receptors in human brain from controls and Parkinsonian subjects. Brain Res. 414: 8-14, 1987.
142. DELAY-GOYET, P., ZAJAC, J.-M., AND ROQUES, B. P.: Effects of repeated treatment with haloperidol on rat striatal neutral endopeptidase EC 3.4.24.11, and on μ and δ opioid binding sites: comparison with chronic morphine and chronic kelatorphan. Neurosci. Lett. 103: 197-202, 1989a.
143. DELAY-GOYET, P., KAYSER, V., ZAJAC, J.-M., GUILBAUD, G., BESSON, J.-M., AND ROQUES, B. P.: Lack of significant changes in μ, δ opioid binding sites and neutral endopeptidase EC 3.4.24.11 in the brain and spinal cord of arthritic rats. Neuropharmacology 28: 1341-1348, 1989b.
144. DEL FIACCO, M., PAXINOS, G., AND CUELLO, A. C.: Neostriatal enkephalin-immmunoreactive neurons project to the globus pallidus. Brain Res. 231: 1-17, 1982.
145. DELMAS, B., GELFI, J., L'HARIDON, R., VOGEL, L. K., SJOSTROM, H., NOREN, O., AND LAUDE, H.: Aminopeptidase N is a major receptor for the enteropathogenic coronavirus TGEV. Nature (Lond.) 357: 417-420, 1992.
146. DESCHODT-LANCKMAN, M., MICHAUX, F., DE PREZ, E., ABRAMOWICZ, D., VANHERWEGHEM, J. L., AND GOLDMAN, M.: Increased serum levels of endopeptidase 24.11 ("enkephalinase") in patients with end-stage renal failure. Life Sci. 45: 133-141, 1989.
147. DESMEULES, J. A., KAYSER, V., GACEL, G., ROQUES, B. P., AND GUILBAUD, G.: The highly selective delta agonist BUBU induces analgesic effect in normal and arthritic rat and this action in not affected by repeated administration of low doses of morphine. Brain Res., in press, 1993.
148. DEVAULT, A., LAZURE, C., NAULT, C., LE MOUAL, H., SEIDAH, N. G., CHRETIEN, M., KAHN, P., POWELL, J., MALLET, J., BEAUMONT, A., ROQUES, B. P., CHINE, P., AND BOILEAU, C.: Amino acid sequence of rabbit kidney neutral endopeptidase 24.11 (enkephalinase) deduced from a complementary DNA. EMBO J. 6: 1317-1322, 1987.
149. DEVAULT, A., SALES, N., NAULT, C., BEAUMONT, A., ROQUES, B. P., CRINE, P., AND BOILEAU, G.: Exploration of the catalytic site of endopeptidase 24-11 by site-directed mutagenesis. Histidine residues 583 and 587 are essential for catalysis. FEBS Lett. 231: 54-58, 1988a.
150. DEVAULT, A., NAULT, C., ZOLLINGER, M., FOURNIÉ-ZALUSKI, M. C., ROQUES, B. P., CRINE, P., AND BOILEAU, G.: Expression of neutral endopeptidase (enkephalinase) in heterologous cos-1 cells: characterization of the recombinant enzyme and evidence for a glutamic acid residue at the active site. J. Biol. Chem. 263: 4033-4040, 1988b.
151. DE WITTE, P., HEIDBREDER AND ROQUES, B. P.: Kelatorphan, a potent enkephalinase inhibitor, and opioid receptor agonists DAGO and DTLET, differentially modulate self-stimulation behaviour depending on the site of administration. Neuropharmacology 28: 667-676, 1989.
152. DICKENSON, A. H.: Enkephalins. A new approach to pain relief? Nature (Lond.) 320: 681-682, 1986.
153. DICKENSON, A. H.: Recent advances in the physiology and pharmacology of pain: plasticity and its implications for clinical analgesia. J. Psychopharmacol. 5: 342-351, 1991.
154. DICKENSON, A. H., SULLIVAN, A., FEENEY, C., FOURNIE-ZALUSKI, M. C., AND
155. DICKENSON, A. H., SULLIVAN, A. F., KNOX, R., ZAJAC, J.-M., AND ROQUES, B. P.: Opioid receptor subtypes in the rat spinal cord: electrophysiological studies with μ and δ opioid receptor agonists in the control of nociception. Brain Res. 413: 36-44, 1987a.
156. DICKENSON, A. H., SULLIVAN, A. F., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Prevention of degradation of endogenous enkephalins produces inhibition of nociceptive neurones in rat spinal cord. Brain Res. 408: 185-191, 1987b.
157. DICKENSON, A. H., SULLIVAN, A. F., AND ROQUES, B. P.: Evidence that endogenous enkephalins and a δ opioid receptor agonist have a common site of action in spinal antinociception. Eur. J. Pharmacol. 148: 437-439, 1988.
158. DICKINSON, K. E. J., TYMIAK, A. A., COHEN, R. B., LIU, E. C.-K., WEBB, M. L., AND HEDBERG, A.: Vascular A10 cell membranes contain an endothelin metabolizing neutral endopeptidase. Biochem. Biophys. Res. Commun. 176: 423-430, 1991.
159. DILTS, R. P., AND KALIVAS, P. W.: Autoradiographic localization of μ-opioid and neurotensin receptors within the mesolimbic dopamine system. Brain Res. 488: 311-327, 1989.
160. DJOKIC, T. D., NADEL, J. A., DUSSER, D. J., SEKIZAWA, K., GRAF, P. D., AND BORSON, D. B.: Inhibitors of neutral endopeptidase potentiate electrically and capsaicin-induced noncholinergic contraction in guinea pig bronchi. J. Pharmacol. Exp. Ther. 248: 7-11, 1989.
161. DOURMAP, N., MICHAEL-TITUS, A., AND COSTENTIN, J.: Acetorphan, an enkephalinase inhibitor, modulates dopaminergic transmission in rat olfactory tubercle, but not in the nucleus accumbens and striatum, Eur. J. Neurosci. 2: 783-787, 1990a.
162. DOURMAP, N., MICHAEL-TITUS, A., AND COSTENTIN, J.: Local enkephalin tonically modulate dopamine release in the striatum: a microdialysis study. Brain. Res. 524: 153-155, 1990b.
163. DUBNER, A., AND RUDA, M. A.: Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 15: 96-103, 1992.
164. DUMAN, R. S., TALLMAN, J. F., AND NESTLER, E. J.: Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus. J. Pharmacol. Exp. Ther. 246: 1033-1039, 1988.
165. 3H]methionine-enkephalin by various rat tissues in vivo and in vitro. Life Sci. 21: 907-914, 1977.
166. DURIEUX, C., CHARPENTIER, B., FELLION, E., GACEL, G., PELAPRAT, D., AND ROQUES, B. P.: Multiple cleavage sites of cholecystokinin heptapeptides by enkephalinase. Peptides 6: 495-501, 1985.
167. 8 analogues by rat brain slices. Neuropeptides 7:1-9, 1986.
168. DUSSAULE, J. C., GRANGE, J. D., WOLF, J. P., LECOMTE, J. M., GROS, C., SCHWARTZ, J. C., BODIN, F., AND ARDAILLOU, R.: Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites. J. Clin. Endocrinol. Metab. 72: 653-659, 1991.
169. DUSSER, D. J., NADEL, J. A., SEKIZAWA, K., GRAF, P. D., AND BORSON, D. B.: Neutral endopeptidase and angiotensin converting enzyme inhibitors potentiate kinin-induced contraction of ferret trachea. J. Pharmacol. Exp. Ther. 244: 531-536, 1988.
170. DUSSER, D. J., JACOBY, D. B., DJOKIC, T. D., RUBINSTEIN, I., BORSON, D. B., AND NADEL, J. A.: Virus induces airway hyperresponsiveness to tachykinins: role of neutral endopeptidase. J. Appl. Physiol. 67: 1504-1511, 1989.
171. OUTRIEZ, I., SALÈS, N., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Pre and post-natal ontogeny of neutral endopeptidase 24-11 ("enkephalinase") studied by in vitro autoradiography in the rat. Experientia 48: 290-300, 1992.
172. DZOLJIC, M. R., RADEMAKER, B., POEL-HEISTERKAMP, A. L., UKPONMWAN, O. E., AND HAFFMANS, J.: Enkephalinase inhibition suppresses naloxone-induced jumping in morphine dependent mice. Arch. Int. Pharmacodyn. Ther. 283: 222-228, 1986.
173. DZOLJIC, M. R., BOKSZANSKA, A., KORENHOF, A. M., KAPLAN, C. D., DZOLJIC, M., RUPREHT, J., ZIJLSTRA, F. J., BRINKMAN, E. C. A., AND CAPPENDIJK, S. L. T.: The effects of orally active enkephalinase inhibitors on morphine withdrawal syndrome. Neuroreport 3: 637-640, 1992.
174. ELLIOT, R. L., MARKS, N., BERG, M. J., AND PORTOGHESE, P. S.: Synthesis and biological evaluation of phosphonomidate peptide inhibitors of enkephalinase and angiotensin converting enzyme. J. Med. Chem. 28: 1208-1216, 1985.
175. EL-SOBKY, A., DOSTROVSKY, J. O., AND WALL, P. D.: Lack of effect of naloxone on pain perception in humans. Nature (Lond.) 263: 783-784, 1976.
176. ERDÖS, E. G., JOHNSON, A. R., AND BOYDEN, N. T.: Hydrolysis of enkephalin by cultured human endothelial cells and by purified peptidyl dipeptidase. Biochem. Pharmacol. 27: 843-845, 1978.
177. ERDÖS, E. G., AND SKIDGEL, R. A.: Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 3: 145-151, 1989.
178. ERDÖS, E. G., WAGNER, B., HARBURY, C. B., PAINTER, R. G., SKIDGEL, R. A., AND XIANG-GUANG, F.: Down-regulation and inactivation of neutral endopeptidase 24.11 (enkephalinase) in human neutrophils. J. Biol. Chem. 264:14519-14523, 1989.
179. EVANS, C. J., KEITH, D. E., MORRISON, H., MAGENDZO, K., AND EDWARDS, R. H.: Cloning of a delta opioid receptor by functional expression. Science 258: 1592-1955, 1992.
180. FAGNY, C., MICHEL, A., LEONARD, I., BERKENBOOM, G., FONTAINE, J., AND DESCHODT-LANCKMAN, M.: In vitro degradation of endothelin-1 by endopeptidase 24.11 (enkephalinase). Peptides 12: 773-778, 1991.
181. FANG, F. G., FIELDS, H. L., AND LEE, N. M.: Action at the mu receptor is sufficient to explain the supraspinal analgesic effects of opiates. J. Pharmacol. Exp. Ther. 238: 1039-1044, 1986.
182. FARACH, H. A., MUNDY, D. I., STRITTMATTER, W. J., AND LENNARZ, W. J.: Evidence for the involvement of metalloendoproteases in the acrosome reaction in sea urchin sperm. J. Biol. Chem. 262: 5483-5487, 1987.
183. FARIS, P. L., KOMISARUK, B. R., WATKINS, L. R., AND MAYER, D. J.: Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219: 310-312, 1983.
184. FIORAMONTI, J., BUENO, L., AND FARGEAS, M. J.: Enhancement of colonic motor response to feeding by central endogenous opiates in the dog. Life Sci. 36: 2509-2514, 1985.
185. FLORAS, P., BIDABE, A. M., CAILLE, J. M., SIMONNET, G., LECOMTE, J. M., AND SABATHIE, M.: Double-blind study of effects of enkephalinase inhibitor on adverse reactions to myelography. Am. J. Neuroradiol. 4: 653-655, 1983.
186. FLORENTIN, D., SASSI, A., AND ROQUES, B. P.: A highly sensitive fluorimetric assay for "enkephalinase", a neutral metalloendopeptidase that releases Tyr-Gly-Gly from enkephalins. Anal. Biochem. 141: 62-69, 1984.
187. FOSSIEZ, F., LEMAY, G., LABONTE, N., PARMENTIER-LESAGE, F., BOILEAU, G., AND CRINE, P.: Secretion of a functional soluble form of neutral endopeptidase 24.11 from a baculovirus-infected insect cell line. Biochem. J., 286: 53-59, 1992.
188. FOURNIÉ-ZALUSKI, M. C.: Design and evaluation of inhibitors of enkephalin degrading enzymes. Neurochem. Int. 12: 375-382, 1988.
189. FOURNIÉ-ZALUSKI, M. C., PERDRISOT, R., GACEL, G., SWERTS, J. P., ROQUES, B. P., AND SCHWARTZ, J. C.: Inhibitory potency of various peptides on enkephalinase activity from mouse striatum. Biochem. Biophys. Res. Commun. 91: 130-135, 1979.
190. FOURNIÉ-ZALUSKI, M. C., LLORENS, C., GACEL, G., MALFROY, B., SWERTS, J. P., LECOMTE, J. M., SCHWARTZ, J. C., AND ROQUES, B. P.: Synthesis and biological properties of highly potent enkephalinase inhibitors. In Peptides 1980, ed. by K. Brunfeld, pp. 476-481, Scriptor, Copenhagen, Denmark, 1981a.
191. FOURNIÉ-ZALUSKI, M. C., SOROCA, E., GACEL, G., ROQUES, B. P., LLORENS, C., MALFROY, B., AND SCHWARTZ, J. C.: Study of crucial components in enkephalinase inhibitors and synthesis of photoaffinity labels and tritiated derivatives. In Proceedings of the VIth American Peptide Symposium, ed. by D. H. Rich and E. Gross, pp. 425-428, Pierce Chemical Company, University of Wisconsin-Madison, 1981b.
192. FOURNIÉ-ZALUSKI, M. C., SOROCA-LUCAS, E., WAKSMAN, G., SCHWARTZ, J. C., AND ROQUES, B. P.: Differential recognition of "enkephalinase" and angiotensin-converting-enzyme by new carboxyalkyl inhibitors. Life Sci. 31: 2947-2954, 1982.
193. FOURNIÉ-ZALUSKI, M. C., CHAILLET, P., SOROCA-LUCAS, E., COSTENTIN, J., AND ROQUES, B. P.: New carboxyalkyl inhibitors of brain "enkephalinase": synthesis, biological activity and analgesic properties. J. Med. Chem. 26: 60-65, 1983.
194. FOURNIÉ-ZALUSKI, M. C., CHAILLET, P., BOUBOUTOU, R., COULAUD, A., CHÉROT, P., WAKSMAN, G., COSTENTIN, J., AND ROQUES, B. P.: Analgesic effects of kelatorphan, a new highly potent inhibitor of multiple enkephalin degrading enzymes. Eur. J. Pharmacol. 102: 525-528, 1984a.
195. FOURNIÉ-ZALUSKI, M. C., LUCAS, E., WAKSMAN, G., AND ROQUES, B. P.: Differences in the structural requirements for selective interaction with neutral metalloendopeptidase (enkephalinase) or angiotensin converting enzyme: molecular investigation by use of new thiol inhibitors. Eur. J. Biochem. 139: 267-274, 1984b.
196. FOURNIÉ-ZALUSKI, M. C., COULAUD, A., BOUBOUTOU, R., CHAILLET, P., DEVIN, J., WAKSMAN, G., COSTENTIN, J., AND ROQUES, B. P.: New bidentates as full inhibitors of enkephalin degrading enzymes: synthesis and analgesic properties. J. Med. Chem. 28: 1158-1169, 1985.
197. 1H]NMR configuration correlation for retro-inverso dipeptides: application to the determination of the absolute configuration of "enkephalinase" inhibitors. Relationships between stereochemistry and enzyme recognition. J. Med. Chem. 29: 751-757, 1986.
198. FOURNIÉ-ZALUSKI, M. C., HERNANDEZ, J. F., SOLEILHAC, J. M., RENWART, N., PEYROUX J., XIE, J., AND ROQUES, B. P.: Enkephalin degrading enzyme inhibitors: crucial role of the C-terminal residue on the inhibitory potencies of retro-hydroxamate dipeptides. Int. J. Pept. Protein Res. 33: 146-153, 1989.
199. FOURNIÉ-ZALUSKI, M. C., CORIC, P., TURCAUD, S., BRUETSCHY, L., NOBLE, F., AND ROQUES, B. P.: Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation. J. Med. Chem. 35: 1259-1266, 1992a.
200. FOURNIÉ-ZALUSKI, M. C., CORIC, P., TURCAUD, S., LUCAS, E., NOBLE, F., MALDONADO, R., AND ROQUES, B. P.: Mixed-inhibitor-prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J. Med. Chem., 35: 2473-2481, 1992b.
201. 125I]RB104, a new potent inhibitor of neutral endopeptidase-24,11 and its use in detecting nanogram quantities of the enzymes by "Inhibitor Gel Electrophoresis". Proc. Natl. Acad. Sci. USA 89: 6388-6392, 1992c.
202. FULCHER, I. S., CHAPLIN, M. F., AND KENNY, A. J.: Endopeptidase 24-11 purified from frog intestine is differently glycosylated from that in kidney. Biochem. J. 215: 317-323, 1983.
203. FULLER, F., PORTER, J. G., ARFSTEN, A. E., MILLER, J., SCHILLING, J. W., SCARBOROUGH, R. M., LEWICKI, J. A., AND SCHENK, D. B.: Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. J. Biol. Chem. 263: 9395-9401, 1988.
204. GACEL, G., FOURNIÉ-ZALUSKI, M. C., FELLION, E., AND ROQUES, B. P.: Evidence of the preferential involvement of μ-receptors in analgesia using enkephalins highly selective for peripheral μ or δ receptors. J. Med. Chem. 24: 1119-1124, 1981.
205. GACEL, G., DAUGÉ, V., BREUZÉ, P., DELAY-GOYET, P., AND ROQUES, B. P.: Development of conformationally constrained linear peptides exhibiting a high affinity and pronounced selectivity for δ opioid receptors. J. Med. Chem. 31: 1891-1897, 1988.
206. GALINA, Z. H., AND KASTIN, A. J.: Existence of anti-opiate systems as illustrated by MIF-1/Tyr-MIF-1. Life Sci. 39: 2153-2159, 1986.
207. GALL, C., LAUTERBORN, J., BURKS, D., AND SEROOGY, K.: Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res. 403: 403-408, 1987.
208. GARCIA-LOPEZ, M. T., GONZALEZ-MUNIZ, R., HERRANZ, R., BRAVO, H., AND NARANJO, J. R.: Synthesis and analgesic properties of N-phosphorylated derivatives of Phe-Ala and Phe-Gly. Int. J. Pept. Protein Res. 26: 174-178, 1985.
209. GAUDOUX, F., BOILEAU, G., AND CRINE, P.: Localization of neprilysin (EC 3.4.24.11) mRNA in rat brain by in situ hybridization. J. Neurosci. Res., in press, 1993.
210. GEE, N. S., MATSAS, R., AND KENNY, A. J.: A monoclonal antibody to kidney endopeptidase 24-11. Its application in immunoadsorbent purification of the enzyme and immunofluorescent microscopy of kidney and intestine. Biochem. J. 214: 377-386, 1983.
211. GEE, N. S., BOWES, M. A., BUCK, P., AND KENNY, A. J.: An immunoradiometric assay for endopeptidase 24-11 shows it to be a widely distributed enzyme in pig tissues. Biochem. J. 228: 119-126, 1985.
212. GENEST, J., AND CANTIN, M.: Atrial natriuretic factor. Circulation 75 (Suppl. I): 118-124, 1987.
213. GHELARDINI, C., BARTOLINI, A., MALMBERG-AIELLO, P., MALCANGIO, M., AND GIOTTI, A.: The enkephalinase inhibitor thiorphan greatly potentiates antinociception induced by very low doses of naloxone. Pharmacol. Res. 21: 631-632, 1989.
214. GIORGI, O., PIBIRI, M. G., ONGINI, E., TRAMPUS, M., AND BIGGIO, G.: The neutral endopeptidase 24.11 (enkephalinase) inhibitor SCH 32615, increases dopamine metabolism in the nucleus accumbens of the rat. Eur. J. Pharmacol. 196: 137-142, 1991.
215. 5-enkephalin in brain slices using peptidase inhibitors and anti-aminopeptidase M antibodies. Mol. Pharmacol. 29: 281-287, 1986.
216. GLIMCHER, P. W., GIOVINO, A. A., MARGOLIN, D. H., AND HOEBEL, B. G.: Endogenous opiate reward induced by an enkephalinase inhibitor, thiorphan, injected into the ventral midbrain. Behav. Neurosci. 98: 262-268, 1984.
217. GMEREK, D. E., KATZ, J. L., FRANCE, C. P., AND WOODS, J. H.: Systemic and intracerebroventricular effects of opioid peptides in withdrawn morphine-dependent rhesus monkeys. Life Sci. 33 (Suppl. I): 361-369, 1983.
218. GOMEZ-MONTERREY, I., TURCAUD, S., LUCAS, E., BRUETSCHY, L., ROQUES, B. P., AND FOURNIÉ-ZALUSKI, M. C.: Exploration of neutral endopeptidase (EC 3.4.24.11) active site by a series of new thiol containing inhibitors. J. Med. Chem. 36: 87-96, 1993.
219. GOODLAD, R. A., AND WRIGHT, N. A.: Peptides and epithelial growth regulation. Experientia 43: 780-784, 1987.
220. GOODMAN, M., AND CHOREV, M.: On the concept of linear modified retro-peptide structures. Ace. Chem. Res. 12: 1-7, 1979.
221. GORDON, E. M., CUSHMAN, D. W., TUNG, R., CHEUNG, H. S., WANG, F. L., AND DELANEY, N. G.: Rat brain enkephalinase: characterization of the active site using mercaptopropanoyl amino acid inhibitors and comparison with angiotensin-converting enzyme. Life Sci. 33: 113-116, 1983.
222. GORDON, E. M., GODGREY, J. D., DELONEY, N. G., ASAAD, M. M., VON-LANGEN, D., AND CUSHMAN, D. W.: Design of novel inhibitors of aminopeptidases, synthesis of peptide-derived diamino thiols and sulfur replacement analogues of bestatin. J. Med. Chem. 31: 2199-2211, 1988.
223. GORENSTEIN, C., AND SNYDER, S. H.: Two distinct enkephalinases: solubilization, partial purification and separation from angiotensin converting enzyme. Life Sci. 25: 2065-2070, 1979.
224. GREAVES, M. F., BROWN, G., RAPSON, N. T., AND LISTER, T. A.: Antisera to acute lymphoblastic leukemia cells. Clin. Immunol. Immunopathol. 4: 67, 1975.
225. GREENBERG, R., AND O'KEEFE, E. H.: Thiorphan potentiation of stress-induced analgesia in the mouse. Life Sci. 31: 1185-1188, 1982.
226. GROS, C., GIROS, B., AND SCHWARTZ, J. C.: Identification of aminopeptidase M as an enkephalin-inactivating enzyme in rat cerebral membranes. Biochemistry 24: 2179-2185, 1985.
227. GROS, C., GIROS, B., SCHWARTZ, J. C., VLAICULESCU, A., COSTENTIN, J., AND LECOMTE J. M.: Potent inhibition of cerebral aminopeptidases by carbaphethiol, a parenterally active-compound. Neuropeptides 12: 111-118, 1988.
228. GROS, C., SOUQUE, A., SCHWARTZ, J. C., DUCHIER, J., COURNOT, A., BAUMER, P., AND LECOMTE, J. M.: Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan. Proc. Natl. Acad. Sci. USA 86: 7580-7584, 1989.
229. GUANDALINI, S., FASANO, A., RAO, M. C., FEROLA, A., MIGLIAVACCA, M., MARCHESANO, G., AND RUBINO, A.: Effects of loperamide on intestinal ion transport. J. Pediatr. Gastroenterol. Nutr. 3: 593-601, 1984.
230. GUYON, A., ROQUES, B. P., FOUCAUD, A., GUYON, F., CAUDE, M., PERDRISOT, R., AND SCHWARTZ, J. C.: Enkephalin degradation in mouse brain studied by a new HPLC method: further evidence for the involvement of a carbosydipeptidase. Life Sci. 25: 1605-1612, 1979.
231. HACHISU, M., TAKAHASHI, H., HIRANUMA, T., SHIBAZABI, Y., AND MURATA, S.: Relationship between enkephalinase inhibition by thiorphan in vivo and its analgesic activity. J. Pharmacobio.-Dyn. 8: 701-710, 1985.
232. HACHISU, M., HIRANUMA, T., MURATA, S., AOYAGI, T., AND UMEZAWA, H.: Analgesic effect of actinonin, a new potent inhibitor of multiple enkephalin degrading enzymes. Life Sci. 41: 235-240, 1987.
233. HAFFMANS, J., AND DZOLJIC, M. R.: Inhibition of enkephalinase activity attenuates naloxone precipitated withdrawal symptoms. Gen. Pharmacol. 18: 103-105, 1987.
234. HAFFMANS, J., WALSUM, M. V., VAN AMSTERDAM, J. C. C., AND DZOLJIC, M. R.: Phelorphan, an inhibitor of enzymes involved in the biodegradation of enkephalins, affected the withdrawal symptoms in chronic morphine dependent rats. Neuroscience 22: 233-236, 1987.
235. HALL, M., MILEY, F., AND STEWART, J.: Modulation of blood pressure by substance P: opposite effects of N- and C-terminal fragments on anesthetized rats. Life Sci. 40: 1909-1914, 1987.
236. HALL, M. E., MILEY, F., AND STEWART, J.: The role of enzymatic processing in the biological actions of substance P. Peptides, 10: 895-901, 1989a.
237. HALL, M. E., MILEY, F., AND STEWART, J.: Cardiovascular effects of substance P peptides in the nucleus of the solitary tract. Brain Res. 497: 280-290, 1989b.
238. HAMBROOK, J. M., MORGAN, B. A., RANCE, M. J., AND SMITH, C. F. C.: Mode of deactivation of the enkephalins by rat and human plasma and rat brain homogenates. Nature (Lond.) 263: 782-783, 1976.
239. HAMEL, E., AND BEAUDET, A.: Opioid receptors in rat neostriatum: radioautographic distribution at the electron microscopic level. Brain Res. 401: 239-257, 1987.
240. HAMET, P., TREMBLAY, J., PANG, S. C., GARCIA, R., THIBAULT, G., GUTKOWSKA, J., CANTIN, M., AND GENEST, J.: Effect of native and synthetic atrial natriuretic factor on cGMP. Biochem. Biophys. Res. Commun. 123: 515-527, 1984.
241. HAMET, P., PANG, S. C., AND TREMBLAY, J.: Atrial natriuretic factor induced egression of cGMP in cultured vascular smooth muscle and endothelial cell. J. Biol. Chem. 264: 12364-12369, 1989.
242. HAMMER, R.: Ontogeny of opiate receptors in the rat medial preoptic area: critical periods in regional development. Int. J. Dev. Neurosci. 3: 541-548, 1985.
243. HANGAUER, D. G., MONZINGO, A. F., AND MATTHEWS, B. W.: An interactive computer graphics study of thermolysin-catalyzed peptide cleavage and inhibition by N-carboxymethyl dipeptides. Biochemistry 23: 5730-5741, 1984.
244. HASLANGER, M. F., SYBERTZ, E. J., NEUSTADT, B. R., SMITH, E. M., NECHUTA, T. L., AND BERGER, J.: Carboxyalkyl dipeptides with atrial natriuretic factor potentiating and antihypertensive activity. J. Med. Chem. 32: 737-739, 1989.
245. HAUTEFEUILLE, M., BRANTI, V., DUMONTIER, A. M., AND DESJEUX, J. F.: Effect of a β-casomorphin analog on ion transport in rabbit ileum: evidence for a cholinergic mediation. Regul. Pept. 12 (Suppl. 4): 219-220, 1985.
246. HAVEMANN, U., AND KUSCHINSKY, K: Locomotor activity of rats after injection of various opioids into the nucleus accumbens and the septum medial. Naunyn Schmeidebergs Arch. Pharmacol. 331: 175-180, 1985.
247. HEIDBREDER, C., ROQUES, B. P., VANDERHAEGHEN, J. J., AND DE WITTE, P.: Kelatorphan, a potent enkephalinase inhibitor, presents opposite properties when injected intracerebroventricularly or into the nucleus accumbens on intracranial self-stimulation. Neurochem. Int. 12: 347-350, 1988.
248. HEIDBREDER, C., GEWISS, M., LALLEMAND, S., ROQUES, B. P., AND DE WITTE, P.: Inhibition of enkephalin metabolism and activation of mu- or delta-opioid receptors elicit opposite effects on reward and motility in the ventral mesencephalon. Neuropharmacology 31: 293-298, 1992.
249. HÉLÈNE, A., BEAUMONT, A., AND ROQUES, B. P.: Functional residues at the active site of aminopeptidase N. Eur. J. Biochem. 196: 385-393, 1991.
250. HÉLèNE, A., MILHIET, P. E., HAOUAS, H., BOUCHEIX, C., BEAUMONT, A., AND ROQUES, B. P.: Effects of monoclonal antibodies raised against the common acute lymphoblastic leukemia antigen on endopeptidase-24.11 activity. Biochem. Pharmacol. 43: 809-814, 1992.
251. HERNANDEZ, J. F., SOLEILHAC, J. M., ROQUES, B. P., AND FOURNIÉ-ZALUSKI, M. C.: Retro-inverso concept applied to the mixed inhibitors of enkephalin-degrading enzymes. J. Med. Chem. 31: 1825-1831, 1988.
252. HERSH, L. B.: Solubilization and characterization of two rat brain membrane bound aminopeptidases active on Met-enkephalin. Biochemistry 20: 2345-2350, 1981.
253. HERSH, L. B., AND MORIHARA, K.: Comparison of the subsite specificity of the mammalian neutral endopeptidase 24-11 (enkephalinase) to the bacterial neutral endopeptidase thermolysin. J. Biol. Chem. 261: 6433-6437, 1986.
254. HEYMAN, J. S., JIANG, Q., ROTHMAN, R. B., MOSBERG, H. I., AND PORRECA, F.: Modulation of μ-mediated antinociception by & agonists: characterization with antagonists. Eur. J. Pharmacol. 169: 43-52, 1989.
255. 8) and related peptides in rats and mice: effects of naloxone and peptidase inhibitors. Neuropharmacology 26: 289-300, 1987.
256. HIRAMATSU, M., NABESHIMA, T., FUKAYA, H., FURUKAWA, H., AND KAMEYAMA, T.: Potentiation of phencyclidine-induced stereotyped behaviors in rats by thiorphan and bestatin. Eur. J. Pharmacol. 120: 69-74, 1986.
257. HIRATA, Y., MATSUOKA, H., HAYAKAWA, H., SUGIMOTO, T., SUZUKI, E., SUGIMOTO, T., KANGAWA, K., AND MATSUO, H.: Role of endogenous atrial natriuretic peptide in regulating sodium excretion in spontaneously hypertensive rats. Effects of neutral endopeptidase inhibition. Hypertension 17: 1025-1032, 1991.
258. HOLODAY, J. W., TORTELLA, F. C., LONG, J. B., BELENKY, G. L., AND HITZEMANN, R. J.: Endogenous opioids and their receptors: evidence for involvement in the postictal effects of electroconvulsive shock. Ann. NY Acad. Sci. 462: 124-139, 1986.
259. HONDA, I., KOHROGI, H., YAMAGUCHI, T., AND O, M., AND ARAKI, S.: Enkephalinase inhibitor potentiates substance P- and capsaicin-induced bronchial smooth muscle contractions in humans. Am. Rev. Respir. Dis. 143: 1416-1418, 1991.
260. HONG, J. S., YANG, H. Y. T., FRATTA, W., AND COSTA, E.: Chronic treatment with haloperidol accelerates biosynthesis of enkephalin in rat striatum. Brain Res. 160: 192-195, 1979.
261. HORSTHEMKE, B., HAMPRECHT, B., AND BAUER, K.: Heterogenous distribution of enkephalin-degrading peptidases between neuronal and glial cells. Biochem. Biophys. Res. Commun. 115: 423-429, 1983.
262. HOUDI, A. A., AND VAN LOON, G. R.: Haloperidol-induced increase in striatal concentration of the tripeptide, Tyr-Gly-Gly, provides an index of increased enkephalin release in vivo. J. Neurochem. 54: 1360-1366, 1990.
263. HOWELL, S., MURRAY, H., SCOTT, C. S., TURNER, A. J., AND KENNY, A. J: A highly sensitive e.l.i.s.a. for endopeptidase-24.11, the common acute-lymphoblastic-leukaemia antigen (CALLA, CD-10), applicable to material of porcine and human origin. Biochem. J. 278: 417-421, 1991.
264. HUCKELBRIDGE, F., HUDSPITH, B., LYDYARD, P., AND BROSTOFF, J.: Stimulation of human peripheral lymphocytes by methionine enkephalin and δ-selective opioid analogues. Immunopharmacology 19: 87-91, 1990.
265. HUI, K. S., WANG, Y. J., AND LAJTHA, A.: Purification and characterization of an enkephalin aminopeptidase from rat brain membranes. Biochemistry 22: 1062-1067, 1983.
266. HWANG, J. K., AND WARSHEL, A.: Why ion pair reversal by protein engineering is unlikely to succeed ? Nature (Lond.) 334: 270-272, 1988.
267. IIJIMA, H., GERARD, N. P., SQUASSONI, C., EWIG, J., FACE, D., DRAZEN, J. M., KIM, Y. A., SHRIVER, B., HERSH, L. B., AND GERARD, C.: Exon 16 del: a novel form of human neutral endopeptidase (CALLA). Am. J. Physiol. 262:L725-L729, 1992.
268. INAGAMI, T.: Atrial natriuretic factor. J. Biol. Chem. 266: 3043-3046, 1989.
269. INDIG, F. E., PECHT, M., TRAININ, N., BURSTEIN, Y., AND BLUMBERG, S.: Hydrolysis of thymic humoral factor γ2 by neutral endopeptidase (EC 3.4.24.11). Biochem. J. 278: 891-894, 1989.
270. JACKSON, B., CUBELA, R., AND JOHNSTON, C. I.: Angiotensin-converting enzyme (ACE) measurement in human serum using radioinhibitor ligand binding. Aust. J. Exp. Biol. Med. Sci. 64: 149-155, 1986.
271. JACKSON, M. C., AND SEWELL, R. D. E.: Thiorphan and bestatin: effect on food intake. Br. J. Pharmacol. 86: 459P, 1985.
272. JALAL, F., LEMAY, G., ZOLLINGER, M., BERTHELOT, A., BOILEAU, G., AND CRINE, P.: Neutral endopeptidase, a major brush border protein of the kidney proximal nephron is directly targeted to the apical domain when expressed in Madrin-Darbey kidney cells. J. Biol. Chem. 266: 19826-19857, 1991.
273. JARDINE, A. G., CONNELL, J. M., NORTHRIDGE, D., DILLY, S. G., CUSSANS, N. J., DAVIDSON, G., DOYLE, J., LECKIE, B. L., AND LEVER, A. F.: The atriopeptidase inhibitor UK 69578 increases atrial natriuretic factor and causes a natriuresis in normal humans. Am. J. Hypertens. 3: 661-667, 1990.
274. JIVEGARD, L., POLLARD, H., MOREAU, J., SCHWARTZ, J. C., THUNE, A., AND SVANIK, J.: Naloxone-reversible inhibition of gall-bladder mucosa fluid secretion in experimental cholecystitis in the cat by acetorphan, an enkephalinase inhibitor. Clin. Sci. 77: 49-54, 1989.
275. JOCHEN, A., AND BERHANU, P.: Effects of metalloendoprotease inhibitors on insulin binding, internalization and processing in adipocytes. Biochem. Biophys. Res. Commun. 142: 205-212, 1987.
276. JOHNSON, A. R., ASHTON, J., SCHULZ, W. W., AND ERDOS, E. G.: Neutral metalloendopeptidase in human lung tissue and cultured cells. Am. Rev. Respir. Dis. 132: 564-568, 1985.
277. JONGENEEL, C. V., BOUVIER, J., AND BAIROCH, A.: A unique signature identifies a family of zinc-dependent metallopeptidase. FEBS Lett. 242: 211-214, 1989.
278. KACHEL, G., RUPPIN, H., HAGEL, J., BARINA, W., MEINHARDT, M., AND DOMSCHKE, W.: Human intestinal motor activity and transport: effects of a synthetic opiate. Gastroenterology 90: 85-93, 1986.
279. KACHUR, J. F., MILLER, R. J., AND FIELD, M.: Control of guinea-pig intestinal electrolyte secretion by a delta-opioid receptor. Proc. Natl. Acad. Sci. USA 77: 2753-2756, 1980.
280. KAHN, J. C., PATEY, M., DUBOIS-RANDE, J. L., MERLET, P., CASTAIGNE, A., LIM-ALEXANDRE, C., LECOMTE, J. M., DUBOC, D., GROS, C., AND SCHWARTZ, J. C.: Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 335: 118-119, 1990.
281. KALIVAS, P. W., AND BRONSON, M.: Mesolimbic dopamine lesions produce an augmented behavioural responses to enkephalin. Neuropharmacology 24: 931-936, 1985.
282. KALIVAS, P. W., WIDERLOW, E., STANLEY, D., BREESE, G., AND PRANGE, A. J.: Enkephalin action on the mesolimbic system: a dopamine-dependent and a dopamine-independent increase in locomotor activity. J. Pharmacol. Exp. Ther. 227: 229-237, 1983.
283. KALIVAS, P. W., RICHARDSON-CARLSON, R., AND VAN ORDEN, G.: Cross-sensitization between foot shock stress and enkephalin-induced motor activity. Biol. Psychiatry 21: 939-950, 1986.
284. KALSO, E. A., SULLIVAN, A. F., MCQUAY, H. J., AND DICKENSON, A. H.: Spinal antinociception by Tyr-D.Ser(OtBu)-Gly-Phe-Leu-Thr, a selective δ-opioid receptor agonist. Eur. J. Pharmacol. 216: 97-101, 1992.
285. KALSO, E. A., SULLIVAN, A. F., MCQUAY, H. J., AND DICKENSON, A. H.: Cross-tolerance between μ-opioid and α2-adrenergic receptors but not between μ-and δ-opioid receptors in the spinal cord of the rat. J. Pharmacol. Exp. Ther., in press, 1993.
286. KAMEI, J., KAWASHIMA, N., AND KASUYA, Y.: Naloxone-induced analgesia in diabetic mice. Eur. J. Pharmacol. 210: 339-341, 1992.
287. KANAZAWA, M., CASLEY, D. J., SYBERTZ, E. J., HASLANGER, M. F., AND JOHNSTON, C. I.: Localization and characterization of neutral metalloendopeptidase (EC 3.4.24.11), the degradative enzyme for atrial natriuretic peptide, in rat kidney using a radioiodinated neutral metalloendopeptidase inhibitor. J. Pharmacol. Exp. Ther. 261: 1231-1237, 1992.
288. KAYSER, V., BENOIST, J. M., GAUTRON, M., AND GUILBAUD, G.: Effects of ES52, an enkephalinase inhibitor, on responses of ventrobasal thalamic neurons in rat. Peptides 5: 1159-1165, 1984.
289. KAYSER, V., FOURNIÉ-ZALUSKI, M. C., GUILBAUD, G., AND ROQUES, B. P.: Potent antinociceptive effects of kelatorphan (a highly efficient inhibitor of multiple enkephalin degrading enzymes) systemically administered in normal and arthritic rats. Brain Res. 497: 94-101, 1989.
290. KAYSER, V., AND GUILBAUD, G.: Increase in the threshold of a nociceptive test induced by naloxone in morphine tolerant rats. Brain Res. 344: 306-364, 1985.
291. KENNY, J.: Cell surface peptidases are neither peptide nor organ specific. Trends Biochem. Sci. 11: 40-42, 1986.
292. KENNY, A. J., AND STEPHENSON, S. L.: Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett. 232: 1-8, 1988.
293. KENNY, A. J., STEPHENSON, S. L., AND TURNER, A. J.: Cell surface peptidases. In Mammalian Ectoenzymes, ed by A. J. Kenny and A. J. Turner, pp. 169-210, Elsevier Science Publisher, Amsterdam, The Netherlands, 1987.
294. KENT, J. L., PERT, C. B., AND HERKENHAM, M.: Ontogeny of opiate receptors in rat forebrain: visualization by in vitro autoradiography. Dev. Brain Res. 2: 487-504, 1982.
295. KERR, M. A., AND KENNY, A. J.: The molecular weight and properties of a neutral metallo-endopeptidase from rabbit kidney brush border. Biochem. J. 137: 489-495, 1974a.
296. KERR, M. A., AND KENNY, A. J.: The purification and specificity of a neutral endopeptidase from rabbit kidney brush border. Biochem. J. 137: 477-488, 1974b.
297. KESTER, W. R., AND MATTHEWS, B. W.: Comparison of the structures of carboxypeptidase A and thermolysin. J. Biol. Chem. 252: 7704-7709, 1977a.
298. KESTER, W. R., AND MATTHEWS, B. W.: Crystallographic study of the binding of dipeptide inhibitors of thermolysin: implication for the mechanism of catalysis. Biochemistry 16: 2506-2516, 1977b.
299. KIEFFER, B. L., BEFORT, K., GAVERIAUX-RUFF, C. AND HIRTH, C. G.: The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. USA 83: 12048-12052, 1992.
300. KILPATRICK, D. L., AND ROSENTHAL, J. L.: The proenkephalin gene is widely expressed within the male and female reproductive systems of the rat and hamster. Endocrinology 119: 370-374, 1986.
301. KIM, Y. A., SHRIVER, B., AND HERSH, L. B.: Mutational analysis reveals only one catalytic histidine in neutral endopeptidase ("enkephalinase"). Biochem. Biophys. Res. Commun. 184: 883-887, 1992a.
302. KIM, Y. A., SHRIVER, B., QUAY, T., AND HERSH, L. B.: Analysis of the importance of arginine 102 in neutral endopeptidase (enkephalinase) catalysis. J. Biol. Chem. 267: 12330-12335, 1992b.
303. KIMURA, A., IWAMOTO, I., NAKAGAWA, N., TOMIOKA, H., AND YOSHIDA, S.: Neutral endopeptidase (EC 3.4.24.11) does not hydrolyze recombinant human interleukin-1β. Immunol. Lett. 28: 109-114, 1991.
304. KIOUSSI, C., CRINE, P., AND MATSAS, R.: Endopeptidase-24.11 is suppressed in myelin-forming but not in non-myelin forming Schwann cells during development of the rat sciatic nerve. Neuroscience 50: 69-84, 1992.
305. KIOUSSI, C., AND MATSAS, R.: Endopeptidase-24.11, a cell-surface peptidase of central nervous sytem neurons, is expressed by Schwann cells in the pig peripheral nervous system. J. Neurochem. 57: 431-440, 1991.
306. KOEHN, J. A., NORMAN, J. A., JONES, B. N., LE SUEUR, L., SAKANE, Y., AND GHAI, R. D.: Degradation of atrial natriuretic factor by kidney cortex membranes. J. Biol. Chem. 262: 11623-11627, 1987.
307. KOEPKE, J. P., TYLER, L. D., TRAPANI, A. J., BOVY, P. R., SPEAR, K. L., OLINS, G. M., AND BLAINE, E. H.: Interaction of non-guanylate cyclase-linked atriopeptin receptor ligand and endopeptidase inhibitor in conscious rats. J. Pharmacol. Exp. Ther. 249: 172-176, 1989.
308. KOHROGI, H., NADEL, J. A., MALFROY, B., GORMAN, C., BRIDENBAUGH, R., PATTON, J. S., AND BORSON, D. B.: Recombinant human enkephalinase (neutral endopeptidase) prevents cough induced by tachikinins in awake guinea pigs. J. Clin. Invest. 84: 781-786, 1989.
309. KOOB, G. F., WALL, T. L., AND BLOOM, F. E.: Nuclueus accumbens as a substrate for the aversive stimulus effects of opiate withdrawal. Psychopharmacology 98: 530-534, 1989.
310. KOSEKI, C., HAYASKI, Y., TORIKAI, S., AND FURUYA, M.: Localization of binding sites for α rat ANP in rat kidney. Am. J. Physiol. 250: F210-F216, 1986.
311. KRIETER, P. A., OLINS, G. M., VERRETT, S. P., AND DURLEY, R. C.: In vivo metabolism of atrial natriuretic peptide: identification of plasma metabolites and enzymes responsible for their generation. J. Pharmacol. Exp. Ther. 249: 411-417, 1989.
312. KROMER, E. P., ELSNER, D., KAHLES, H. W., AND RIEGGER, G. A.: Effects of atriopeptidase inhibitor UK 79300 on left ventricular hydraulic load in patients with congestive heart failure. Am. J. Hypertens. 4: 460-463, 1991.
313. KRUSE, T. A., BOLUND, L., GRZESCHIK, K. H., AND ROPERS, S. C.: Assignment of the human aminopeptidase N (peptidase E) gene to chromosome 15q13-qter. FEBS
314. LAI, A. P., Moss, F. M., ARMITAGE, R. J., AND CRAWLEY, J. C.: Bone marrow macrophages and megakariocytes express common acute lymphoblastic leukemia antigen. Leuk. Res. 9: 1155-1159, 1985.
315. LAKE, J. R., HAMMOND, M. W., SHADDOX, R. C., HUNSICKER, L. M., YANG, H. Y. T., AND MALIN, D. H.: IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci. Lett. 132: 29-32, 1991.
316. LARVOL, L., BAUMER, P., BERARD, H., CERF, M., AND LECOMTE, J. M.: Rôle des enképhalines endogènes dans la motricité duodénale postprandiale. Gastroenterol. Clin. Biol. 15: A142, 1992.
317. LASCHKA, E., TESCHEMACHER, H., MEHRAIN, P., AND HERZ, A.: Sites of action of morphine involved in the development of physical dependence in rats. Psychopharmacologia (Berl.) 46: 141-147, 1976.
318. LASHER, R. S., LUTZ, E. M., MULHOLLAND, F., SANDERSON, R., STEWART, J. M., AND BUBLITZ, C.: Immunocytochemical localization of endopeptidase-24.11 in the nucleus tractue solitarius of the rat brain. Neurosci. Lett. 117: 43-49, 1990.
319. LAVIGNE, G. J., MILLINGTON, W. R., AND MUELLER, G. P.: The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment. Neuropeptides 21: 119-129, 1992.
320. LEHY, T., PUCCIO, F., CHARIOT, J., AND LABEILLE, D.: Stimulating effect of bombesin on the growth of gastrointestinal tract and pancreas in suckling rats. Gastroenterology 90: 1942-1949, 1986.
321. LE BARS, D., BOURGOIN, S., VILLANUEVA, L., CLOT, A. M., HAMON, M., AND CESSELIN, F.: Involvement of the dorsolateral funiculi in the spinal release of Met-enkephalin-like material triggered by heterosegmental noxious mechanical stimuli. Brain Res. 412: 190-195, 1987.
322. LE BIEN, T. W., AND MCCORMACK, R. T.: The common acute lymphoblastic leukemia antigen (CD10) - emancipation from a functional enigma. Blood 73: 625-634, 1989.
323. LECAVALLIER, H., CRINE, P., AND MALO, C.: Presence of endopeptidase 24.11 during the ontogeny of the small intestine in different species. Biol. Neonate 56: 342-350, 1989.
324. LECOMTE, J. M., COSTENTIN, J., VLAICULESCU, A., CHAILLET, P., MARCAIS-COLLADO, H., LLORENS-CORTES, C., LEBOYER, M., AND SCHWARTZ, J. C.: Pharmacological properties of acetorphan, a parenterally active enkephalinase inhibitor. J. Pharmacol. Exp. Ther. 237: 937-944, 1986.
325. LECOMTE, J. M., BAUMER, P., LIM, C., DUCHIER, J., COURNOT, A., DUSSAULE, J. C., ARDAILLOU, R., GROS, C., CHAIGNON, B., SOUQUE, A., AND SCHWARTZ, J. C.: Stereoselective protection of exogenous and endogenous atrial natriuretic factor by enkephalinase inhibitors in mice and humans. Eur. J. Pharmacol. 179: 65-73, 1990.
326. LEMAY, G., WAKSMAN, G., ROQUES, B. P., CRINE, P., AND BOILEAU, G.: Fusion of a cleavable signal peptide to the ectodomain of neutral endopeptidase (EC 3.4.24.11) results in the secretion of an active enzyme in cos-1 cells. J. Biol. Chem. 264: 15620-15623, 1989.
327. LEMAY, G., ZOLLINGER, M., WAKSMAN, G., ROQUES, B. P., CRINE, P., AND BOILEAU, G.: Recombinant neutral endopeptidase-24,11 expressed in mouse neuroblastoma cells is associated with neurite membranes. Biochem. J. 264: 447-452, 1990.
328. LE MOINE, C., NORMAND, E., AND BLOCH, B.: Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene. Proc. Natl. Acad. Sci. USA 88: 4205-4209, 1991.
329. LE MOUAL, H., DEVAULT, A., ROQUES, B. P., CRINE, P., AND BOILEAU, G.: Identification of glutamic acid 646 as a zinc-coordinating residue in endopeptidase-24.11. J. Biol. Chem. 266: 15670-15674, 1991.
330. LENNARZ, W. J., AND STRITTMATTER, W. J.: Cellular functions of metalloendoproteinases. Biochim. Biophys. Acta 1071: 149-158, 1991.
331. LEONE, P., POCOCK, D., AND WISE, R. A.: Morphine-dopamine interaction: ventral tegmental morphine increases nucleus accumbens dopamine release. Pharmacol. Biochem. Behav. 39: 469-472, 1991.
332. LETARTE, M., VERA, S., TRAN, R., ADDIS, J. B., ONIZUKA, R. J., QUACKENBUSH, E. J., JONGENEEL, C. V., AND MCINNES, R. R.: Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase. J. Exp. Med. 168: 1247-1253, 1988.
333. LIPSCOMB, W. V.: Carboxypeptidase A mechanisms. Proc. Natl. Acad. Sci. USA 77: 3875-3878, 1980.
334. LIVINGSTON, S. J., SEWELL, R. D. E., ROONEY, K. F., AND SMITH, H. J.: Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan. Psychopharmacology 94: 540-544, 1988.
335. LLORENS, C., GACEL, G., SWERTS, J. P., PERDRISOT, R., FOURNIÉ-ZALUSKI, M. C., SCHWARTZ, J. C., AND ROQUES, B. P.: Rational design of enkephalinase inhibitors: substrate specificity of enkephalinase studied from inhibitory potency of various peptides. Biochem. Biophys. Res. Commun. 96: 1710-1715, 1980.
336. LLORENS, C., MALFROY, B., SCHWARTZ, J. C., GACEL, G., ROQUES, B. P., ROY, J., MORGAT, J. L., JAVOY-AGID, F., AND AGID, Y.: Enkephalin dipeptidyl Carboxypeptidase (enkephalinase) activity: selective radioassay, properties and regional distribution in human brain. J. Neurochem. 39: 1081-1089, 1982.
337. LLORENS, C., AND SCHWARTZ, J. C.: Enkephalinase activity in rat peripheral organs. Eur. J. Pharmacol. 69: 113-116, 1981.
338. LLORENS-CORTES, C., GROS, C., AND SCHWARTZ, J. C.: Study of endogenous Tyr-Gly-Gly a putative enkephalin metabolite in mouse brain: validation of a radioimmunoassay, localisation and effects of peptidase inhibitors. Eur. J. Pharmacol. 119: 183-191, 1985.
339. LLORENS-CORTES, C., GROS, C., AND SCHWARTZ, J. C.: Steady-state level and turnover rate of the tripeptide Tyr-Gly-Gly as indexes of striatal enkephalin release in vivo and their reduction during pentobarbital anesthesia. Proc. Natl. Acad. Sci. USA 83: 6226-6230, 1986.
340. LLORENS-CORTES, C., GROS, C., SCHWARTZ, J. C., CLOT, A. M., AND LE BARS, D.: Changes in levels of the tripeptide Tyr-Gly-Gly as an index of enkephalin release in the spinal cord: effects of noxious stimuli and parenterally active peptidase inhibitors. Peptides 10: 609-614, 1989.
341. LLORENS-CORTES, C., GIROS, B., AND SCHWARTZ, J. C.: A novel potential metallopeptidase derived from the enkephalinase gene by alternative splicing. J. Neurochem. 55: 2146-2148, 1990.
342. LLORENS-CORTES, C., ZINI, S., GROS, C., AND SCHWARTZ, J. C.: Dopaminergic regulation of enkephalin release. J. Neurochem. 56: 1368-1375, 1991.
343. LLORENS-CORTES, C., HUANG, H., VICART, P., GASC, J. M., PAULIN, D., AND CORVOL, P.: Identification and characterization of neutral endopeptidase in endothelial cells from venous or arterial origins. J. Biol. Chem. 267: 14012-14018, 1992.
344. LLORENS-CORTES, C., AND SCHWARTZ, J. C.: Changes in turnover of cerebral monoamines following inhibition of enkephalin metabolism by thiorphan and bestatin. Eur. J. Pharmacol. 104: 369-374, 1984.
345. 1 dependent stimulation of motor activity and stereotypes. Behav. Pharmacol. 1: 38, 1989.
346. LOOK, A., ASHMUN, R., SHAPIRO, L., AND PEIPER, S.: Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J. Clin. Invest. 83: 1299-1307, 1989.
347. LORKOWSKI, G., ZIJDERHAND-BLEEKEMOLEN, J. E., ERDÖS, E. G., VON FIGURA, K., AND HASILIK, A.: Neutral endopeptidase-24.11 (enkephalinase). Biosynthesis and localization in human fibroblasts. Biochem. J. 248: 345-350, 1987.
348. LÖTVALL, J. O., SKOOGH, B. E., BARNES, P. J., AND CHUNG, K. F.: Effects of aerosolised substance P on lung resistance in guinea-pigs: a comparison between inhibition of neutral endopeptidase and angiotensin-converting enzyme. Br. J. Pharmacol. 100: 69-72, 1990.
349. LUCY, J. A.: Do hydrophobic sequences cleaved from cellular polypeptides induce membrane fusion reactions in vivo? FEBS Lett. 166: 223-231, 1984.
350. LUNDBERG, J. M., HÖKFELT, T., MARTLING, C. R., SARIA, A., AND CUELLO, C.: Substance P-immunoreactive sensory nerves in the lower respiratory tract of various mammals including man. Cell Tissue Res. 235: 251-261, 1984.
351. MAACK, T., SUZUKI, M., ALMEIDA, F. A., NUSSENZVEIG, D., SCARBOROUGH, R. M., MCENROE, G. A., AND LEWICKI, J. A.: Physiological role of silent receptors of atrial natriuretic factor. Science 238: 675-678, 1987.
352. 2 with μ and δ opioid antinociception in the rat spinal cord. Neuropeptides 16: 213-218, 1990.
353. MAILLEUX, P., PRZEDBORSKI, S., BEAUMONT, A., VERSLIJPE, M., DEPIERREUX, M., LEVIVIER, M., KITABGI, P., ROQUES, B. P., AND VANDERHAEGHEN, J. J.: Neurotensin high affinity binding sites and endopeptidase 24.11 are present respectively in the meningothelial and in the fibroblastic components of human meningiomas. Peptides 11: 1245-1253, 1990.
354. MALDONADO, R., DAUGÉ, V., CALLEBERT, J., VILLETTE, J. M., FOURNIÉ-ZALUSKI, M. C., FÉGER, J., AND ROQUES, B. P.: Comparison of selective and complete inhibitors of enkephalin degrading enzymes on morphine withdrawal syndrome. Eur. J. Pharmacol. 165: 199-207, 1989.
355. MALDONADO, R., FÉGEH, J., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Differences in physical dependence induced by selective μ or δ opioid agonists and by endogenous enkephalins protected by peptidase inhibitors. Brain Res. 520: 247-254, 1990a.
356. 1-dopamine receptors blockade facilitates behavioural responses to endogenous enkephalins protected by kelatorphan administered intraaccumbens in rats. Neuropharmacology 29: 215-223, 1990b.
357. MALDONADO, R., STINUS, L., GOLD, L. H., AND KOOB, G. F.: Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J. Pharmacol. Exp. Ther. 261: 669-677, 1992.
358. MALDONADO, R., DERRIEN, M., NOBLE, F., AND ROQUES, B. P.: Association of a peptidase inhibitor and a CCK-B antagonist strongly potentiates antinociception mediated by endogenous enkephalins. Submitted.
359. MALFROV, B., AND SCHWARTZ, J. C.: Properties of enkephalinase from rat kidney: comparison of dipeptidyl-carboxypeptidase and endopeptidase activities. Biochem. Biophys. Res. Commun. 106: 276-285, 1982.
360. MALFROY, B., AND SCHWARTZ, J. C.: Comparison of dipeptidylcarboxypeptidase and endopeptidase activities in the three enkephalin-hydrolysing metallopeptidases: angiotensin converting enzyme, thermolysin and enkephalinase. Biochem. Biophys. Res. Commun. 130: 372-378, 1985.
361. 3H-enkephalins in mouse brain: pharmacological characterization, localisation and effects of chronic treatment with morphine. In Characteristics and Function of Opioids, ed. by J. M. Van Ree and L. Terenius, pp. 485-486, Elsevier North Holland Biochemical Press, Amsterdam, The Netherlands, 1978a.
362. MALFROY, B., SWERTS, J. P., GUYON, A., ROQUES, B. P., AND SCHWARTZ, J. C.: High-affinity enkephalin-degrading peptidase in mouse brain and its enhanced activity following morphine. Nature (Lond.) 276: 523-526, 1978b.
363. MALFROY, B., SWERTS, J. P., LLORENS, C., AND SCHWARTZ, J. C.: Regional distribution of a high-affinity enkephalin-degrading peptidase (enkephalinase) and effects of lesions suggest localization in the vicinity of opiate receptors in brain. Neurosci. Lett. 11: 329-334, 1979.
364. MALFROY, B., SCHOFIELD, P. R., KUANG, W. J., SEEBURG, P. H., MASON, A. J., AND HENZEL, W. J.: Molecular cloning and aminoacid sequence of rat enkephalinase. Biochem. Biophys. Res. Commun. 144: 59-66, 1987.
365. MALFROY, B., KUANG, W. J., SEEBURG, P. H., MASON, A. J., AND SCHOFIELD, P. R.: Molecular cloning and aminoacid sequence of human enkephalinase (neutral endopeptidase). FEBS Lett. 229: 206-210, 1988.
366. MALIN, D. H., LAKE, J. R., HAMILTON, R. F., AND SKOLNICK, M. H.: Augmentated analgesic effects of enkephalinase inhibitors combined with transcranial electrostimulation. Life Sci. 44: 1371-1376, 1989.
367. 2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. Peptides 11: 277-280, 1990a.
368. 2-like mammalian octapeptide: possible role in opiate dependence and abstinence. Peptides 11: 969-972, 1990b.
369. MALIN, D. H., LAKE, R. J., LEYRA, J. E., HAMMOND, M. V., ROGILLIO, R. B., ARCANGELI, H. R., LUDGATE, K., MOORE, G. M., AND PAYZA, K.: Analog of neuropeptide FF attenuates morphine abstinence syndrome. Peptides 12: 1011-1014, 1991.
370. MARÇAIS-COLLADO, H., UCHIDA, G., COSTENTIN, J., SCHWARTZ, J. C., AND LECOMTE, J. M.: Naloxone reversible antidiarrheal effects of enkephalinase inhibitors. Eur. J. Pharmacol. 144: 125-132, 1987.
371. MARCEL, D., POLLARD, H., VERROUST, P., SCHWARTZ, J. C., AND BEAUDET, A.: Electron microscopic localization of immunoreactive enkephalinase (EC 3.4.24.11) in the neostriatum of the rat. J. Neurosci. 10: 2804-2817, 1990.
372. MARGULIES, K. B., PERRELLA, M. A., MCKINLEY, L. J., AND BURNETT, J. C.: Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J. Clin. Invest. 88: 1636-1642, 1991.
373. MARI, B., CHECLER, F., PONZIO, G., PEYRON, J. F., MANIE, S., FARAHIFAR, D., ROSSI, B., AND ANBERGER, P.: Jurkat T cells express a functional neutral endopeptidase activity (CALLA) involved in T cell activation. EMBO J., 11: 3875-3885, 1992.
374. MAROUX, S.: Structural and topological aspects. In Mammalian Ectoenzymes, ed by A. J. Kenny and A. J. Turner, pp. 15-45, Elsevier Science Publisher, Amsterdam, The Netherlands, 1987.
375. MATSAS, R., FULCHER, I. S., KENNY, A. J., AND TURNER, A. J.: Substance P and Leu-enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli. Proc. Natl. Acad. Sci. USA 80: 3111-3114, 1983.
376. 8. FEBS Lett. 175: 124-128, 1984a.
377. MATSAS, R., KENNY, A. J., AND TURNER, A. J.: The metabolism of neuropeptides: the hydrolysis of peptides including enkephalins, tachykinins and their analogues, by endopeptidase 24.11. Biochem. J. 223: 433-440, 1984b.
378. MATSAS, R., STEPHENSON, S. L., HRYSZBO, J., KENNY, A. J., AND TURNER, A.: The metabolism of neuropeptides. Phase separation of synaptic membrane preparations with Triton X114 reveals the presence of aminopeptidase N. Biochem. J. 231: 445-449, 1985.
379. MATSAS, R., KENNY, A. J., AND TURNER, A. J.: In immunohistochemical study of endopeptidase 24-11 (enkephalinase) in the pig nervous system. Neurosci. 18: 991-1012, 1986.
380. 5-enkephalin-induced antinociception. Jpn J. Pharmacol. 46: 205-210, 1988.
381. MATTHEWS, B. W.: Structural basis of the action of thermolysin and related zinc peptidases. Acc. Chem. Res. 21: 333-340, 1988.
382. MAUBORGNE, A., BOURGOIN, S., BENOLIEL, J. J., HIRSH, H., BERTHIER, J. L., HAMON, M., AND CESSELIN, F.: Enkephalinase is involved in the degradation of endogenous substance P released from slices of rat substantia nigra. J. Pharmacol. Exp. Ther. 243: 674-680, 1987a.
383. MAUBORGNE, A., LUTZ, O., LEGRAND, J. C., HAMON, M., AND CESSELIN, F.: Opposite effects of δ and μ opioid receptor agonists on the in vitro release of substance P-like material from the rat spinal cord. J. Neurochem. 48: 529-537, 1987b.
384. MAUBORGNE, A., BOURGOIN, S., BENOLIEL, J. J., HAMON, M., AND CESSELIN, F.: Is substance P released from slices of the rat spinal cord inactivated by peptidase(s) distinct from both "enkephalinase" and "angiotensin-converting enzyme"? Neurosci. Lett. 123: 221-225, 1991.
385. MAYER, D. J., PRICE, D. D., AND RAFII, A.: Antagonism of acupuncture analgesia in man by the narcotic antagonist naloxone. Brain Res. 121: 368-372, 1977.
386. MAYER, D. J., AND WATKINS, L. R.: Neural mechanisms of endogenous opiate and non-opiate analgesia systems. In Quo Vadis 1982, ed. by R. Boigegrain, J. Cros, M. Moore, J. P. Muyard, and R. Roncucci, pp 121-152, Sanofi Recherche Montpellier, France 1984.
387. MCDERMOTT, J. R., DUDD, P. R., EDWARDSON, J. A., HARDY, J. A., AND SMITH, A. J.: Pathway of inactivation of cholecystokinin octapeptide (CCK8) by synaptosomal fractions. Neurochem. Int. 5: 641-647, 1983.
388. MCDONALD, J. K., AND BARRETT, A. J.: Mammalian proteases. In A Glossary and Bibliography, Vol. 2: Exopeptidases, Academic Press, London, UK, 1986.
389. MCLENNAN, A., AND MAIER, S. F.: Coping and the stress-induced potentiation of stimulant stereotypy in the rat. Science 219: 1091-1093, 1983.
390. 7 degradation by inhibitors of dipeptidyl carboxypeptidase. J. Pharmacol. Exp. Ther. 239: 174-178, 1986.
391. 8-induced antinociception. Eur. J. Pharmacol. 133: 185-190, 1987.
392. MENOZZI, D., Gu, Z. F., MATON, P. N., AND BUNNETT, N. W.: Inhibition of peptidases potentiates enkephalin-stimulated contraction of gastric muscle cells. Am. J. Physiol. 261: G476-G484, 1991.
393. MEUCCI, E., DELAY-COVET, P., ROQUES, B. P., AND ZAJAC, J. M.: Binding in vivo of selective μ and δ opioid agonists: opioid receptor occupancy by endogenous enkephalins. Eur. J. Pharmacol. 171: 167-178, 1989.
394. MEYNADIER, J., DALMAS, S., LECOMTE, J. M., GROS, C., AND SCHWARTZ, J. C.: Potent analgesic effects of inhibitors of enkephalin metabolism administered intrathecally to cancer patients. Pain Clin. 2: 201-206, 1988.
395. MICHAEL-TITUS, A., DOURMAP, N., CALINE, H., COSTENTIN, J., AND SCHWARTZ, J. C.: Role of endogenous enkephalins in locomotion and nociception studied with peptidase inhibitors in two inbred strains of mice. Neuropharmacology 28: 117-122, 1989.
396. MICHAEL-TITUS, A., DOURMAP, N., COSTENTIN, J., AND SCHWARTZ, J. C.: Role of delta opioid receptors in the effects of inhibitors of enkephalin-degrading peptidases on the horizontal and vertical components of locomotion in mice. Neuropeptides 15: 89-100, 1990.
397. MICHEL, J. B., AND ARNAL, J. F.: Le facteur atrial natriurétique. Arch. Mal. Coeur 83: 2111-2121, 1990.
398. MIHARA, S., AND NORTH, R. A.: Opioids increase potassium conductance in guinea-pig submucous neurones by activating delta-receptors. Br. J. Pharmacol. 88: 315-322, 1986.
399. MIKUNI-TAKAGARI, Y., AND CHENG, Y. S.: Metalloproteinases in endochondral bone formation: appearance of tissue inhibitor-resistant metalloproteinases. Biochem. Biophys. Res. Commun. 259: 576-588, 1987.
400. MILHIET, P. E.: Modulation et trafic cellulaire de l'endopeptidase neutre. Applications au ciblage. Thèse de l'Université René Descartes, Paris, France, 1992.
401. MILHIET, P. E., BEAUMONT, A., GARBAY-JAUREGUIBERRY, C., AND ROQUES, B. P.: Increase of neutral endopeptidase activity with cellular density and enzyme modulation with inhibitor on human Reh6 cell line. Biochem. Pharmacol. 43: 1711-1715, 1992a.
402. MILHIET, P. E., DENNIN, F., GIOCONDI, M. C., LE GRIMELLEC, C., GARBAY-JAUREGUIBERRY, C., BOUCHEIX, C., AND ROQUES, B. P.: Detection of neutral endopeptidase-24.11/CD10 by flow cytometry and photomicroscopy using a new fluorescent inhibitor. Anal. Biochem. 205: 57-64, 1992b.
403. MILHIET, P. E., GIOCONDI, M. C., CRINE, P., GARBAY-JAUREGUIBERRY, C., LE GRIMELLEC, C., AND ROQUES, B. P.: Fate of a fluorescent inhibitor of endopeptidase-24.11 using enzyme-transfected MDCK cells. Monoclonal antibody-induced internalization of inhibitor-enzyme complex. J. Cell. Biol., in press, 1993.
404. MIMURA, T., NAKAMURA, Y., NISHINO, J., SAWAYAMA, T., KOMIYA, T., DEGUCHI, T., KITA, A., NAKAMURA, H., AND MATSUMOTO, J.: A novel class of enkephalinase inhibitors containing a C-terminal sulfo group. J. Med. Chem. 35: 602-608, 1992.
405. MORIN-SURUN, M. P., BOUDINOT, E., GACEL, G., CHAMPAGNAT, J., ROQUES, B. P., AND DENAVIT-SAUBIÉ, M.: Different effects of delta and mu opiates agonists on respiration. Eur. J. Pharmacol. 98: 235-240, 1984.
406. MORIN-SURUN, M. P., BOUDINOT, E., FOURNIE-ZALUSKI, M. C., CHAMPAGNAT, J., ROQUES, B. P., AND DENAVIT-SAUBIE: Control of breathing by endogenous opioid peptides: possible involvement in sudden infant death syndrome. Neurochem. Int. 20: 103-107, 1992.
407. MORRIS, B. J., AND HERZ, A.: Control of opiate receptor number in vivo: simultaneous κ-receptor down-regulation and μ-receptor up-regulation following chronic agonist/antagonist treatment. Neuroscience 29: 433-442, 1989.
408. 2 antagonists. Neuroscience 25: 525-532, 1988.
409. 5-enkephalin in the substantia gelatinosa of the cat spinal cord. Eur. J. Pharmacol. 140: 195-201, 1987.
410. MULDER, A. H., WARDEH, F., HOGENBOOM, F., AND FRANKHUYZEN, A. L.: Selectivity of various opioid peptides towards delta-, kappa, and mu-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the brain. Neuropeptides 14: 99-104, 1989.
411. MUMFORD, R. A., ZIMMERMAN, M., BROEKE, J. T., TAUB, D., JOSHUA, H., ROTHROCK, J. W., HIRSHFIELD, J. M., SPRINGER, J. P., AND PATCHETT, A. A.: Inhibition of porcine kidney "enkephalinase" by substituted-N-carboxymethyl dipeptides. Biochem. Biophys. Res. Commun. 109: 1303-1309, 1982.
412. MUNDY, D. I., AND STRITTMATER, J.: . Requirement for metalloendoprotease in exocytosis: evidence in mast cells and adrenal chromaffin cells. Cell 40: 645-656, 1985.
413. MÜNZEL, T., KURZ, S., HOLTZ, J., BUSSE, R., STEINHAUER, H., JUST, H., AND DREXLER, H.: Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 86: 1089-1098, 1992.
414. MURTHY, L. R., GLICK, S. D., ALMENOPF, J., WILK, S., AND ORLOWSKI, M.: Inhibitors of an enkephalin degrading membrane bound metalloendopeptidase: analgesic properties and effects on striatal enkephalin levels. Eur. J. Pharmacol. 102: 305-313, 1984.
415. NABESHIMA, T., KATOH, A., AND KAMEYAMA, T.: Inhibition of enkephalin degradation attenuated stress-induced motor suppression (conditioned suppression of motility). J. Pharmacol. Exp. Ther. 244: 303-309, 1988.
416. NADEL, J. A.: Neutral endopeptidase modulation of neurogenic inflammation in airways. Eur. Respir. J. 3: 645s-651s, 1990.
417. NADEL, J. A., AND BORSON, D. B.: Modulation of tachykinins and bradykinins by enkephalinase. In Mechanisms in Asthma: Pharmacology Physiology and Managements, pp. 123-130, Alan R. Lies, Inc., New York, 1988.
418. NEEDELMAN, P., BLAINE, E. H., GREENWALD, J. E., MICHENER, M. L., SAFER, C. B., STOCKMANN, P. T., AND TOLUNAY, H. E.: The biological pharmacology of atrial peptides. Annu. Rev. Pharmacol. Toxicol. 29: 23-54, 1989.
419. NEIL, A., KAYSER, V., GACEL, G., BESSON, J. M., AND GUILBAUD, G.: Opioid receptor types and antinociceptive activity in chronic inflammation: both κ-and μ-opiate agonistic effects are enhanced in arthritic rats. Eur. J. Pharmacol. 130: 203-208, 1986.
420. NESTLER, E. J., AND TALLMAN, J. F.: Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus. Mol. Pharmacol. 33: 127-132, 1988.
421. NICHOL, G. M., O'CONNOR, B. J., LECOMTE, J. M., CHUNG, K. F., AND BARNES, P. J.: Effect of neutral endopeptidase inhibitor on airway function and bronchial responsiveness in asthmatic subjects. Eur. J. Clin. Pharmacol. 42: 491-494, 1992.
422. NISHIMURA, E., BUCHAN, A., AND MCINOSH, C.: Autoradiographic localization of μ and δ type opioid receptors in the gastrointestinal tract of the rat and guinea pig. Gastroenterology 91: 1084-1094, 1986.
423. NISHINO, N., AND POWERS, J. C.: Peptidyl hydroxamic acids as inhibitors of thennolysin. Biochemistry 17: 2846-2850, 1978.
424. NOBLE, F., CORIC, P., SOLEILHAC, J. M., TURCAUD, S., DAUGÉ, V., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Analgesic properties of systemically active mixed enkephalin-degrading enzyme inhibitors. In New Leads in Opioid Research, ed. by J. M. Van Ree, A. H. Mulder, U. M. Wiegant, and T. B. Van Wimersma-Greidamus, pp. 83-85, Excerpta Medica, Amsterdam, The Netherlands, 1990.
425. NOBLE, F., SOLEILHAC, J. M., SOROCA-LUCAS, E., TURCAUD, S., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J. Pharmacol. Exp. Ther. 261: 181-190, 1992a.
426. NOBLE, F., TURCAUD, S., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB 101, does not induce either antinociceptive tolerance or cross-tolerance with morphine. Eur. J. Pharmacol. 223: 83-89, 1992b.
427. NOBLE, F., CORIC, P., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB 101. Eur. J. Pharmacol. 223: 94-96, 1992c.
428. NOBLE, F., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Unlike morphine, the endogenous enkephalins protected by RB 101 are unable to establish a conditioned place preference in mice. Eur. J. Pharmacol. 230: 139-149, 1993a.
429. NOBLE, F., MALDONADO, R., FOURNIÉ-ZALUSKI, M. C., GACEL, G., AND ROQUES, B. P.: Selective stimulation of μ or δ opioid receptors by exogenous agonists or endogenous enkephalins protected from degrading enzymes: advantages and limits in analgesia. Ann. Fr. Anesth. Reanim., in press, 1992d.
430. NOBLE, F., DERRIEN, M., AND ROQUES, B. P.: Modulation of opioid analgesia by CCK: evidence of regulatory mechanism between CCK and enkephalin systems in the supraspinal control of pain. Br. J. Pharmacol., in press, 1993b.
431. 7 by inhibiting its degradation in mouse brain. Mol. Pharmacol. 28: 521-526, 1985.
432. NORTH, R. A., AND EGAN, T. M.: Actions and distributions of opioid peptides in peripheral tissue. Br. Med. Bull. 39: 71-78, 1983.
433. NORTHRIDGE, D. B., ALABASTER, C. T., CONNELL, J. M. C., DILLY, S. G., LEVER, A. F., JARDINE, A. G., BARCLAY, P. L., DARGIE, H. J., FINDLAY, I. N., AND SAMUELS, G. M. R.: Effects of UK 69578: a novel atriopeptidase inhibitor. Lancet 2: 591-593, 1989.
434. NORTHRIDGE, D. B., JARDINE, A. G., FINDLAY, I. N., ARCHIBALD, M., DILLY, S. G., AND DARGIE, H. J.: Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure. Am. J. Hypertens. 3: 682-687, 1990.
435. NYBERG, F., LE GREVES, P., SUNDQVIST, C., AND TERENIUS, L.: Characterization of substance P(1-7) and (1-8) generating enzyme in human cerebrospinal fluid. Biochem. Biophys. Res. Commun. 125: 244-250, 1984.
436. O'BRIEN, J. D., THOMPSON, D. G., MCINTYRE, A., BURNHAM, W. R., AND WALKER, E.: Effect of codeine and loperamide on upper intestinal transit and absorption in normal subjects and patients with postvagotomy diarrhoea. Gut 29: 312-318, 1988.
437. OCAIN, T. D., AND RICH, D. H.: Synthesis of sulfur containing analogues of bestatin inhibition of aminopeptidase by α-thiol bestatin analogues. J. Med. Chem. 31: 2193-2199, 1988.
438. O'CONNOR, P., AND CHIPKIN, R. E.: Comparisons between warm and cold water swin stress in mice. Life Sci. 35: 631-639, 1984.
439. OLINS, G. M., KRIETER, P. A., TRAPANI, A. J., SPEAR, K. L., AND BOVY, P. R.: Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo. Mol. Cell. Endocrinol. 61: 201-208, 1989.
440. OLSEN, J., CORVELL, G. M., KONIGSHOFER, F. G., DANIELSEN, E. M., MOLLER, J., LAUSTSEN, L., HAUSEN, O. C., WELINDER, F. G., ENGBERG, J., HUNZIBER, W., SPIERS, M., SJOSTROM, H., AND NOREN, O.: Complete amino acid sequence of human intestinal aminopeptidase N as deduced from cloned cDNA. FEBS Lett. 238: 307-314, 1988.
441. ONDETTI, M. A., AND CUSHMAN, D. W.: Angiotensin-converting enzyme inhibitors: biochemical properties and biological action. Crit. Rev. Biochem. 16: 381-411, 1984.
442. ONDETTI, M. A., RUBIN, B., AND CUSHMAN, D. W.: Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196: 441-444, 1977.
443. OSHITA, S., YAKSH, T. L., AND CHIPKIN, R.: The antinociceptive effects of intrathecally administered SCH 32615, an enkephalinase inhibitor in the rat. Brain Res. 515: 143-148, 1990.
444. OSTROWSKI, N. L., HATFIELD, C. B., AND CAGGIULA, A. R.: The effects of low doses of morphine on the activity of dopamine containing cells and on behavior. Life Sci. 31: 2347-2350, 1982.
445. PARSONS, C. G., AND HERZ, A.: Peripheral opioid receptors mediating antinociception in inflammation. Evidence for activation by enkephalin-like opioid peptides after cold water swim stress. J. Pharmacol. Exp. Ther. 255: 795-802, 1990.
446. PASQUINI, F., BEAUDET, A., BOCHET, P., ROSSIER, J., AND ROQUES, B. P.: Electron microscopic localization of delta opioid receptors in rat brain. Soc. Neurosci. Abst. 14: 353, 1988.
447. PASQUINI, F., BOCHET, P., GARBAY-JAUREGUIBERRY, C., ROQUES, B. P., ROSSIER, J., AND BEAUDET, A.: Electron microscopic localization of photoaffinity-labelled delta opioid receptors in the neostriatum of the rat. J. Comp. Neurol. 326: 229-244, 1992.
448. PATEY, G., DE LA BAUME, S., SCHWARTZ, J. C., GROS, C., FOURNIÉ-ZALUSKI, M. C., LUCAS-SOROCA, E., AND ROQUES, B. P.: Selective protection of methionine enkephaline released from brain slices by thiorphan, a potent enkephalinase inhibitor. Science 212: 1153-1155, 1981.
449. PELHAM, J., MEYER, B., HERRMANN, R., DAVIS, R., RAPHAEL, C., KRAFT, N., AND ATKINS, R.: Monoclonal antibody-ricin conjugate cytotoxic to cells expressing the common acute lymphoblastic leukemia antigen (CALLA). Pathology 19: 124-130, 1987.
450. 2]-Met-enkephalinamide: a potent, long-lasting synthetic pentapeptide analgesic. Science 194: 330-332, 1976.
451. PETIT, F., HAMON, M., FOURNIÉ-ZALUSKI, M. C., ROQUES, B. P., AND GLOWINSKI, J.: Further evidence for a role of δ opiate receptors in the presynaptic regulation of newly synthesized dopamine release. Eur. J. Pharmacol. 126: 1-19, 1986.
452. PHAM, I., EL AMRANI, A. I. K., FOURNIÉ-ZALUSKI, M. C., CORVOL, P., ROQUES, B. P., AND MICHEL, J. B.: Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive doca-salt rats. J. Cardiol. Res. 20:847-857, 1992.
453. PHAM, I., GONZALEZ, W., EL AMRANI, A. I. K., FOURNIÉ-ZALUSKI, M. C., PHILIPPE, M., LABOULANDINE, I., ROQUES, B. P., AND MICHEL, J. B.: Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor in experimental hypertension. J. Pharmacol. Exp. Ther., in press, 1993.
454. 5-enkephalinamide into the ventral tegmental area. Behav. Brain Res. 5: 225-229, 1982.
455. PICKERING, D. S., KRISHNA, M. V., MILLER, D. C., AND CHAN, W. W. C.: Structural requirements for specific inhibition of microsomal aminopeptidase by mercaptoamines. Arch. Biochem. Biophys. 239: 368-374, 1985.
456. PIERART, M. E., NAJIDOVSKI, T., APPELBOOM, T. E., AND DESCHODT-LANCKMAN, M. M.: Effect of human endopeptidase 24.11 ("enkephalinase") on IL-1-induced thymocyte proliferation activity. J. Immunol. 140: 3808-3811, 1988.
457. PINSKY, C., DUA, A. K., AND LABELLA, F. S.: Peptidase inhibitors reduce opiate narcotic withdrawal signs, including seizure activity, in the rat. Brain Res. 243: 301-307, 1982.
458. POHL, M., MAUBORGNE, A., BOURGOIN, S., BENOLIEL, J. J., HAMON, M., AND CESSELIN, F.: Neonatal capsaicin treatment abolishes the modulations by opioids of substance P release from rat spinal cord slices. Neurosci. Lett. 96: 102-107, 1989.
459. POHL, M., BENOLIEL, J. J., BOURGOIN, S., LOMBARD, M. C., MAUBORGNE, A., TAQUET, H., CARAYON, A., BESSON, J. M., CESSELIN, F., AND HAMON, M.: Regional distribution of calcitonin gene related peptide-, substance P-, cholecystokinin-, Met5-enkephalin- and dynorphin A (1-8)-like materials in the spinal cord and dorsal root ganglia of adult rats: effects of dorsal rhizotomy and neonatal capsaicin. J. Neurochem. 55: 1122-1130, 1990.
460. POLLARD, H., LLORENS-CORTES, C., AND SCHWARTZ, J. C.: Enkephalin receptors on dopaminergic neurons in rat striatum. Nature (Lond.) 268: 745-747, 1977a.
461. POLLARD, H., LLORENS, C., BONNET, J. J., COSTENTIN, J., AND SCHWARTZ, J. C.: Opiate receptors on mesolimbic dopaminergic neurons. Neurosci. Lett. 7: 295-299, 1977b.
462. POLLARD, M., BOUTHENET, M. L., MOREAU, J., SOUIL, E., VERROUST, P., RONCO, P., AND SCHWARTZ, J. C.: Detailed immunoautoradiographic mapping system comparison with enkephalins and SP. Neuroscience 30: 339-376, 1989.
463. POLLARD, H., MOREAU, J., RONCO, P., VERROUST, P., AND SCHWARTZ, J. C.: Immunoautoradiographic localisation of enkephalinase (EC 3.4.24.11) in rat gastrointestinal tract. Neuropeptides 19: 169-178, 1991.
464. PORRECA, F., GALLIGAN, J. J., AND BURKS, J. F.: Central opioid receptor involvement in gastrointestinal motility. Trends Pharmacol. Sci. 7: 104-109, 1986.
465. PORRECA, F., JIANG, Q., AND TALLARIDA, R. J.: Modulation of morphine antinociception by peripheral [Leu 5]enkephalin: a synergistic interaction. Eur. J. Pharmacol. 179: 463-468, 1990a.
466. PORRECA, F., LOPRESTI, D., AND WARD, S. J.: Opioid agonist affinity in the guinea-pig ileum and mouse vas deferens. Eur. J. Pharmacol. 179: 129-139, 1990b.
467. POZSGAY, M., MICHAUD, C., LIEBMAN, M., AND ORLOWSKI, M.: Substrate and inhibitor studies of thermolysin like neutral metalloendopeptidase from kidney membrane fractions. Comparison with bacterial thermolysin. Biochemistry 25: 1292-1299, 1986.
468. PRETEL, S., AND PIEKUT, D. T.: Enkephalin, substance P, and serotonin axonal input to c-Fos-like immunoreactive neurons of the rat spinal cord. Peptides 12: 1243-1250, 1991.
469. PRZEWLOCKI, R., HASSAN, A. H. S., LASON, W., EPPLEN, C., HERZ, A., AND STEIN, C.: Gene expression and localization of opioid peptides in immune cells of inflamed tissue: functional role in antinociception. Neuroscience 48: 491-500, 1992.
470. RASMUSSEN, K., BEITNER-JOHNSON, D. B., KRYSTAL, J. H., AGHAJANIAN, G. K., AND NESTLER, E. J.: Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. J. Neurosci. 10: 2308-2317, 1990.
471. RAYA, T. E., LEE, R. W., WESTHOPP, T. B., AND GOLDMAN, S. M.: Captopril restores hemodynamic responsiveness to atrial natriuretic peptide in rats with heart failure. Circulation 80: 1886-1892, 1989.
472. RELTON, J. M., GEE, N. S., MATSAS, R., TURNER, A. J., AND KENNY, A. J.: Purification of endopeptidase 24-11 (enkephalinase) from pig brain by immunoadsorbent chromatography. Biochem. J. 215: 519-523, 1983.
473. RICH, D. H.: Peptidase inhibitors. In Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study and Therapeutic Application of Chemical Compounds, ed. by P. G. Sammes and J. B. Taylor, Vol. 2, p. 391, Pergamon Press, New York, 1990.
474. RICH, D. H., MOON, B. J., AND HARBESON, S.: Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow binding processes. J. Med. Chem. 27: 417-422, 1984.
475. RICHARDS, M., ESPINER, E., FRAMPTON, C., IKRAM, H., YANDLE, T., SOPWITCH, M., AND CUSSANS, N.: Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension 16: 269-276, 1990.
476. RICHARDS, A. M., WITTERT, G., ESPINER, E. A., YANDLE, T. G., FRAMPTON, C., AND IKRAM, H.: EC 24.11 inhibition in man alters clearance of atrial natriuretic peptide. J. Clin. Endocrinol. Metab. 72: 1317-1322, 1991.
477. RICHARDS, A. M., WITTERT, G. A., ESPINER, E. A., YANDLE, T. G., IKRAN, H., AND FRAMPTON, C.: Effects of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circulation Res. 71: 1501-1507, 1992.
478. RIZUI, T. A., WADHA, S., MEHRA, R. D., AND BIJALIN, V.: Ultrastructure of marginal zone during prenatal development of human cord. Exp. Brain Res. 64: 483-490, 1986.
479. RODERICK, S. L., FOURNIÉ-ZALUSKI, M. C., ROQUES, B. P., AND MATTHEWS, B. W.: Thiorphan and retro-thiorphan display equivalent interactions when bound to crystalline thermolysin. Biochemistry 28: 1493-1497, 1989.
480. ROGERS, N. F., AND EL-FAKAHANY, E. E.: Morphine-induced opioid receptor down-regulation detected in intact adult rat brain cells. Eur. J. Pharmacol. 124: 221-230, 1986.
481. RONCO, P., POLLARD, H., GALCERAN, M., DELAUCHE, M., SCHWARTZ, J. C., AND VERROUST, P.: Distribution of enkephalinase (membrane metalloendopeptidase, E. C.3.4.24.11) in rat organs. Detection using a monoclonal antibody. Lab. Invest. 58: 210-217, 1988.
482. ROQUES, B. P.: Enkephalinase inhibitors: rational design and molecular exploration at the active site of the enzyme. Differences with the angiotensin converting enzyme. In Analgesia and Enkephalinases. Quo Vadis 1982, ed. by R. Boigegrain, J. Cros, M. Morre, J. P. Muyard, and R. Roncucci, pp. 185-212, Sanofi Recherche, Montpellier, France, 1984.
483. ROQUES, B. P.: Inhibiteurs d'enképhalinase et exploration moléculaire des différences entre sites actifs de l'enképhalinase et de l'enzyme de conversion de l'angiotensine. J. Pharmacol. (Paris) 16: 5-31, 1985.
484. ROQUES, B. P.: Physiological role of endogenous peptide effectors studied with peptidase inhibitors. Kidney Int. 34: S27-S33, 1988a.
485. ROQUES, B. P: Novel approaches to the pharmacological modification of peptidergic neurotransmission. In Proceedings of the IVth SCI-Royal Society of Chemistry Medicinal Chemistry Symposium, Topics in Medicinal Chemistry, ed. by P. R. Leeming, Vol. 65, pp. 22-42, Royal Society of Chemistry, Cambridge, UK, 1988b.
486. ROQUES, B. P.: New methodological approaches for the vizualisation of neuropeptidergic targets and for non-invasive investigation of grafts in the brain. In Wenner-Green International, symposium series ed. by D. Ottoson and W. Rosténe, Vol. 53, pp. 307-318, Macmillan Press Ltd., 1989.
487. ROQUES, B. P.: What are the relevant features of the distribution, selective binding and metabolism of opioid peptides and how can these be applied to drug design? In Towards a New Pharmacotherapy of Pain, ed. by A. I. Basbaum and J. M. Besson, pp. 257-278, J. Wiley & Sons, New York, 1991.
488. ROQUES, B. P., AND BEAUMONT A.: Neutral endopeptidase-24.11 inhibitors: from analgesics to antihypertensives? Trends Pharmacol. Sci. 11: 245-249, 1990.
489. ROQUES, B. P., AND FOURNIÉ-ZALUSKI, M. C.: A new way to antinociceptive compounds through rational design of enkephalin degrading enzymes inhibitors. In Proceedings of the International Symposium on Medicinal Chemistry, ed. by R. Dalhbom and J. L. G. Nilsson, pp. 134-146, Swedish Pharmaceutical Press, Stockholm, Sweden, 1985.
490. ROQUES, B. P., AND FOURNIÉ-ZALUSKI, M. C.: Enkephalin degrading enzyme inhibitors: a physiological way to new analgesics and psychoactive agents. Natl. Inst. Drug Abuse Res. Monogr. Ser. 70: 128-154, 1986.
491. ROQUES, B. P., FOURNIE-ZALUSKI, M. C., SOROCA, E., LECOMTE, J. M., MALFROY, B., LLORENS, C., AND SCHWARTZ, J. C.: The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature (Lond.) 288: 286-288, 1980.
492. ROQUES, B. P., FOURNIÉ-ZALUSKI, M. C., FLORENTIN, D., WAKSMAN, G., SASSI, A., CHAILLET, P., COLLADO, H., AND COSTENTIN, J.: New enkephalinase inhibitors as probes to differentiate "enkephalinase" and angiotensin-converting-enzyme active sites. Life Sci. 31: 1749-1752, 1982a.
493. ROQUES, B. P., FOURNIÉ-ZALUSKI, M. C., GACEL, G., LUCAS-SOROCA, E., DAVID, M., SCHWARTZ, J. C., MALFROY, B., LLORENS, C., SWERTS, J. P., LECOMTE, J. M., MEUNIER, J. C., MOISAND, C., MORGAT, J. L., AND MAIGRET, B.: Synthèse et études physicochimiques et biologiques de ligands spécifiques des récepteurs enképhalinergiques mu et delta et d'inhibiteurs du système de dégradation des enképhalines endogènes. Acta Chim. Ther. 9: 211-240, 1982b.
494. ROQUES, B. P., LUCAS-SOROCA, E., CHAILLET, P., COSTENTIN, J., AND FOURNIÉ-ZALUSKI, M. C.: Complete differentiation between "enkephalinase" and angiotensin converting enzyme inhibition by retro-thiorphan. Proc. Natl. Acad. Sci. USA 80: 3178-3182, 1983.
495. ROQUES, B. P., DAUGÉ, V., GACEL, G., AND FOURNIE"-ZALUSKI, M. C.: Selective agonists and antagonists of delta opioid receptors and inhibitors of enkephalins metabolism. Potential use in treatment of mental illness. In Biological Psychiatry, Developments in Psychiatry, Vol. 7, ed. by C. Shagass, R. C. Josiassen, W. H. Bridger, K. J. Weise, D. Stoff, and G. M. Simpon, pp. 287-289, Elsevier, New York, 1985.
496. ROSE, C., CAMUS, A., AND SCHWARTZ, J. C.: A serine peptidase responsible for the inactivation of endogenous cholecystokinin in brain. Proc. Natl. Acad. Sci. USA 85: 8326-8330, 1988.
497. RUDA, M. A.: Opiates and pain pathways: demonstration of enkephalin synapses on dorsal horn projection neurones. Science 215: 1523-1524, 1982.
498. 3H]diprenorphine binding. Brain Res. 571: 306-312, 1992a.
499. 3H]pBC264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J. Neurochem 59: 1805-1811, 1992b.
500. RUPREHT, J., UKPONMWAN, O. E., ADMIRAAL, P. V., AND DZOLJIC, M. R.: Effect of phosphoramidon, a selective enkephalinase inhibitor, on nociception and behaviour. Neurosci. Lett. 41: 331-335, 1983.
501. RYAN, J., LEIGHTON, J., KIRKSEY, D., AND MCMAHON, G.: Evaluation of enkephalin analog in men with castor oil induced diarrhea. Clin. Pharmacol. Ther. 39: 40-42, 1986.
502. SALES, N., CHARNAY, Y., ZAJAC, J.-M., DUBOIS, P. M., AND ROQUES, B. P.: Ontogeny of μ and δ opioid receptors and of neutral endopeptidase "enkephalinase" in human spinal cord: an autoradiographic study. J. Chem. Neuroanat. 2: 179-188, 1989.
503. SALÈS, N., OUTRIEZ, I., MAZIERE, B., OTTAVIANI, M., AND ROQUES, B. P.: Neutral endopeptidase 24.11 in rat peripheral tissues: comparative localization by "ex vivo" and "in vitro" autoradiography. Regul. Pept. 33: 209-222, 1991.
504. SALLES, G., CHEN, C. Y., REINHEKZ, E. L., AND SHIPP, M. A.: CD10/NEP is expressed on Thy-1 low B220+ murine B-cell progenitors and functions to regulate stromal cell-dependent lymphopoiesis. Blood 80: 2121-2029, 1992.
505. SATO, M., IKEDA, K., HAGA, S., ALLSOP, D., AND ISHII, T.: A monoclonal antibody to common acute lymphoblastic leukemia antigen (neutral endopeptidase) immunostains senile plaques in the brains of patients with Alzheimer's disease. Neurosci. Lett. 121: 271-273, 1991.
506. SCHIAVO, G., BENFENATI, F., POULAIN, B., ROSSETTO, O., POLVERINO DE LAURETO, P., DASGUPTA, B. R., AND MONTECUCCO, C.: Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature (Lond.) 359: 832-834, 1992.
507. SCHILLER, P. W., MAZIAK, L. A., NGUYEN, T. M. D., GODIN, J., GARCIA, R., DELEAN, A., AND CANTIN, M.: Superactive analogs of the atrial natriuretic peptide (ANP). Biochem. Biophys. Res. Commun. 143: 499-505, 1987.
508. SCHMIDT, C., PEYROUX, J., NOBLE, F., FOURNIE-ZALUSKI, M. C., AND ROQUES, B. P.: Analgesic responses elicited by endogenous enkephalins (protected by mixed peptidase inhibitors) in a variety of morphine-sensitive noxious tests. Eur. J. Pharmacol. 192: 253-262, 1991.
509. SCHWARTZ, J. C.: Metabolism of enkephalins and the inactivating neuropeptidase concept. Trends Neurosci. 6: 45-48, 1983.
510. SCHWARTZ, J. C., MALFROY, B., AND DE LA BAUME, S.: Biological inactivation of enkephalins and the role of enkephalin-dipeptidyl-carboxypeptidase ("enkephalinase") as neuropeptidase. Life Sci. 29: 1715-1740, 1981.
511. SCHWARTZ, J. C., COSTENTIN, J., AND LECOMTE, J. M.: Pharmacology of enkephalinase inhibitors. Trends Pharmacol. Sci. 6: 472-476, 1985.
512. SCOTT YOUNG, W., III, BONNER, T. I., AND BRANN, M. R.: Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA 83: 9827, 1986.
513. SESACK, S. R., AND PICKEL, V. M.: Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: multiple substrates for opiate-dopamine interactions. J. Neurosci. 12: 1335-1350, 1992.
514. SEYMOUR, A. A., SWERDEL, J. N., DELANEY, N. G., ROM, M., CUSHMAN, D. W., AND DEFORREST, J. M.: Effects of ring-opened atrial natriuretic peptides on mean arterial pressure and renal excretion. Fed. Proc. 46: 1296, 1987.
515. SEYMOUR, A. A., SWERDEL, J. N., FENNELL, S.A., DRUCKMAN, S. P., NEUBRECK, R., AND DELANEY, N. G.: Potentiation of the depressor responses to atrial natriuretic peptides in conscious SHR by an inhibitor of neutral endopeptidase. J. Cardiovasc. Pharmacol. 14: 194-204, 1989a.
516. SEYMOUR, A. A., FENNELL, S. A., AND SWERDEL, J. N.: Potentiation of renal effects of atrial natriuretic factor-(99-126) by SQ 29072. Hypertension 14: 87-97, 1989b.
517. SEYMOUR, A. A., ABBOA-OFFEI, B., ASAAD, M. M., AND ROGERS, W. L.: Evaluation of SQ 28603, an inhibitor of neutral endopeptidase, in conscious monkeys. Can. J. Physiol. Pharmacol. 69: 1609-1617, 1991a.
518. SEYMOUR, A. A., NORMAN, J. A., ASAAD, M. M., FENNELL, S. A., LITTLE, D. K., KRATUNIS, V. J., AND ROGERS, W. L.: Antihypertensive and renal activity of SQ 28603, an inhibitor of neutral endopeptidase. J. Cardiovas. Pharmacol. 17: 296-304, 1991b.
519. SEYMOUR, A. A., SWERDEL, J. N., AND ABBOA-OFFEI, B.: Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J. Cardiovasc. Pharmacol. 17: 456-465: 1991c.
520. SEYMOUR, A. A., ASAAD, M. M., ABBOA-OFFEI, B. E., ROVNYAK, P. L., FENNELL, S., AND ROGERS W. L.: Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats. J. Pharmacol. Exp. Ther. 262: 60-70, 1992.
521. SHANG, J. C., HEMOND, M., HEBERT, M., AND PILOTE, M.: How does morphine work on colonic motility? An electromyographic study in the human left and sigmoid colon. Life Sci. 38: 671-676, 1986.
522. SHELDON, R. J., RIVIERE, P. J. M., MALARCHIK, M. E., MOSBERG, H. I., BURKS, T. F., AND PORRECA, F.: Opioid regulation of mucosal ion transport in the mouse isolated jejunum. J. Pharmacol. Exp. Ther. 253: 144-153, 1990.
523. SHIDA, Y., OKABE, M., KURODA, T., MORIMOTO, M., UEDA, R., AND TAKAHASHI, T.: In vivo and in vitro antitumor activity of mitomycin C conjugates at 7-N position through a linker containing thiocarbamate bond with CD10 monoclonal antibody. Biotherapy 5: 97-105, 1992.
524. SHIPP, M. A., RICHARDSON, N. E., SAYRE, P. H., BROWN, N. R., MASTELLER, E. L., CLAYTON, L. K., RITZ, J., AND REINHERTZ, E. L.: Molecular cloning of the common acute lymphoblastic leukemia antigen antigen (CALLA) identifies a type II integral membrane protein. Proc. Natl. Acad. Sci. USA 85: 4819-4823, 1988.
525. SHIPP, M. A., STEPHANO, G. B., SWITZER, S. N., GRIFFIN, J. D., AND REINHERTZ, E. L.: CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophils morphology, migration, and adhesion proteins and its itself regulated by neutrophil activation. Blood 78:1834-1841, 1991a.
526. SHIPP, M. A., TARR, G. E., CHEN, C. Y., SWITZER, S. N., HERSH, L. B., STEIN, H., SUNDAY, M. E., AND REINHERTZ, E. L.: CD10/neutral endopeptidase 24.11 hydrolyses bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc. Natl. Acad. Sci. USA 88: 10662-10666, 1991b.
527. SHOOK, J. E., PELTON, J. T., LEMCK, P. K., PORRECA, F., HRUBY, V., AND BURKS, T. F.: Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: identification of mu receptor-related functions. J. Pharmacol. Exp. Ther. 242: 1-7, 1987.
528. SHOOK, J. E., LEMCKE, P. K., GEHRIG, C. A., HRUBY, V. J., AND BURKS, T. F.: Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation. J. Pharmarcol. Exp. Ther. 249: 83-90, 1989.
529. SIMMONS, M. L., WAGNER, J. J., CAUDLE, R. M., AND CHAVKIN, C.: Endogenous opioid regulation of norepinephrine release in guinea pig hippocampus. Neurosci. Lett. 141: 84-88, 1992.
530. SJÖLUND, B. J., AND ERIKSSON, M. B. E.: The influence of naloxone on analgesia produced by peripheral conditioning stimulation. Brain Res. 173: 295-302, 1979.
531. SMITS, G. J., MCGRAW, D. E., TRAPANI, A. J., AND BLAINE, E. B.: Effect of endopeptidase 24.11 inhibition in conscious cardiomyopathic hamsters. J. Pharmacol. Exp. Ther. 254: 176-179, 1990a.
532. SMITS, G. J., MCGRAW, D. E., AND TRAPANI, A. J.: Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: renal effects. Am. J. Physiol. 258: F1417-F1424, 1990b.
533. SOLEILHAC, J. M., LUCAS, E., BEAUMONT, A., TURCAUD, S., MICHEL, J. B., FICHEUX, D., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: A 94 Kdalton protein, identified as neutral endopeptidase 24.11, can activate atrial natriuretic peptide in the vascular endothelium. Mol. Pharmacol. 41: 609-614, 1992.
534. SONNENBERG, J. L., SAKANE, Y., JENG, A. Y., KOEHN, J. A., ANSELL, J. A., WENNOGLE, L. P., AND GHAI, R. D.: Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides 9: 173-180, 1988.
535. SOUBRIER, F., ALHENC-GELAS, F., HUBERT, C., ALLEGRINI, J., JOHN, M., TREGEAR, G., AND CORVOL, P.: Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl. Acad. Sci. USA 85: 9386-9390, 1988.
536. SPAIN, J. W., ROTH, B. L., AND COSCIA, C. J.: Differential ontogeny of multiple opioid receptors (μ, δ and κ). J. Neurosci. 5: 584-588, 1985.
537. SPILLANTINI, M. G., SICUTERI, F., SALMON, S., AND MALFROY, B.: Characterization of endopeptidase 3.4.24.11 activity in human plasma and cerebrospinal fluid. Biochem. Pharmacol. 39: 1353-1356, 1990.
538. STAUNTON, D. A., DEYO, S. N., SHOEMAKER, W. J., ETTENBERG, A., AND BLOOM, F. E.: Effects of chronic lithium on enkephalin systems and pain responsiveness. Life Sci. 31: 1837-1840, 1982.
539. STEARDO, L., AND NATHANSON, J. A.: Brain barrier tissues: end organs for atriopeptins. Science 235: 470-473, 1987.
540. STEECE, K. A., LEE, J. M., FIELDS, J. Z., DELEON-JONES, F. A., AND RITZMANN, R. F.: Differential down-regulation of delta opioid binding sites during physical dependence on methionine enkephalin in the rat. Life Sci. 44: 1449-1455, 1989.
541. STEIN, C., MILLAN, M. J., YASSOURIDIS, A., AND HERZ, A.: Antinociceptive effects of μ- and κ-agonists in inflammation are enhanced by a peripheral opioid receptor-specific mechanism. Eur. J. Pharmacol. 155: 255-264, 1988.
542. STEIN, C., MILLAN, M. J., SHIPPENBERG, T. S., PETER, K., AND HERZ, A.: Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J. Pharmacol. Exp. Ther. 248: 1269-1275, 1989.
543. STEIN, C., GRAMSCH, C., AND HERZ, A.: Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and β-endorphin. J. Neurosci. 10: 1292-1298, 1990.
544. STEIN, L., AND BELLUZI, J. D.: Brain endorphins and sense of well-being: a psychobiological hypothesis. Adv. Biochem. Pharmacol. 18: 299-311, 1978.
545. STEPHENSON, S. L., AND KENNY, A. J.: The hydrolysis of α human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase 24.11. Biochem. J. 243: 183-187, 1987a.
546. STEPHENSON, S. L., AND KENNY, A. J.: Metabolism of neuropeptides: hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes. Biochem. J. 241: 237-247, 1987b.
547. STEWART, J. R., AND KENNY, A. J.: Proteins of the kidney microvillar membrane. Biosynthesis of endopeptidase-24.11, dipeptidylpeptidase IV and aminopeptidase A and N in pig kidney slices. Biochem. J. 224: 549-558, 1984.
548. STINUS, L., WINNOCK, M. R., AND KELLEY, A. E.: Chronic neuroleptics treatment and mesolimbic dopamine denervation induce behavioral supersensitivity to opiates. Psychopharmacology 85: 323-328, 1985.
549. STINUS, L., NADAUD, D., JAUREGUI, J., AND KELLEY, A. E.: Chronic treatment with five different neuroleptics elicits behavioral supersensitivity to opiate infusion into the nucleus accumbens. Biol. Psychiatry 21: 34-43, 1986.
550. STINUS, L., LE MOAL, M., AND KOOB, G. F.: Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience 37: 767-773, 1990.
551. STONE, R. A., KUWAYAMA, Y., AND LATIES, A. M.: Regulatory peptide in the eye. Experientia 43: 790-800, 1987.
552. 3H]captopril. Localization to a striatonigral pathway. Proc. Natl. Acad. Sci. USA 81: 1599-1603, 1984.
553. STRITTMATTER, S. M., AND SNYDER, S. H.: Angiotensin converting enzyme immunohistochemistry in rat brain and pituitary gland: correlation of isozyme type with cellular localization. Neuroscience 21: 407-420, 1987.
554. STROUSS, G. J., VAN KERKHOF, P., DEKKER, J., AND SCHWARTZ, A. L.: Metalloendoprotease inhibitors block protein synthesis, intracellular transport, and endocytosis in hepatoma cells. J. Biol. Chem. 263: 18197-18204, 1988.
555. SULLIVAN, A. F., AKIL, H., AND BARCHAS, J. D.: In vitro degradation of enkephalin: evidence for cleavage at the Gly-Phe bond. Psychopharmacology 2: 525-531, 1978.
556. SULLIVAN, A. F., DICKENSON, A. H., AND ROQUES, B. P.: δ Opioid mediated inhibitions of acute and prolonged noxious-evoked responses in rat dorsal horn neurones. Br. J. Pharmacol. 98: 1039-1049, 1989.
557. SULLIVAN, J., AND JOHNSON, A. R.: Detection and analysis of neutral endopeptidase from tissues with substrate gel electrophoresis. Biochem. Biophys. Res. Commun. 163: 300-107, 1989.
558. SURPRENANT, A., AND NORTH, R. A.: Mu-opioid receptors and alpha2-adrenoceptors co-exist on myenteric but not on submucous neurones. Neuroscience 16: 425-430, 1985.
559. SWERTS, J. P., PERDRISOT, R., MALFROY, B., AND SCHWARTZ, J. C.: Is enkephalinase identical with angiotensin converting enzyme? Eur. J. Pharmacol. 53: 209-210, 1979a.
560. SWERTS, J. P., PERDRISOT, R., PATEY, G., DE LA BAUME, S., AND SCHWARTZ, J. C.: Enkephalinase is distinct from brain angiotensin converting enzyme. Eur. J. Pharmacol. 57: 279-281, 1979b.
561. SYBERTZ, E. J., CHIU, P. J. S., VEMULAPALLI, S., PITTS, B., FOSTER, C. J., WATKINS, R. W., BARNETT, A., AND HASLANGER, M. F.: SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats. J. Pharmacol. Exp. Ther. 250: 624-631, 1989.
562. SYBERTZ, E. J., CHIU, P. J. S., VEMULAPALLI, S., WATKINS, R., AND HASLANGER, M. F.: Atrial natriuretic factor-potentiating and hypertensive activity of SCH 34826, an orally active neutral endopeptidase inhibitor. Hypertension 15: 152-161, 1990a.
563. SYBERTZ, E. J., CHIU, P. J., WATKINS, R. W., AND VEMULAPALLI, S.: Neutral metallopeptidase inhibition: a novel means of circulatory modulation. J. Hypertens. 8 (Suppl.): S161-S167, 1990b.
564. TAIWO, Y. O., BASBAUM, A. I., PERRY, F., AND LEVINE, J. D.: Paradoxical analgesia produced by low doses of the opiate-antagonist naloxone is mediated by interaction at a site with characteristics of the delta opioid receptor. J. Pharmacol. Exp. Ther. 249: 97-100, 1989.
565. TAM, L. T., ENGELBRECHT, S., TALENT, J. M., GRACY, R. W., AND ERDÖS, E. G.: The importance of disulfide bridges in human endopeptidase (enkephalinase) after proteolytic cleavage. Biochem. Biophys. Res. Commun. 133: 1182-1192, 1985.
566. TAMBURINI, P. P., KOEHN, J. A., GILLIGAN, J. P., CHARLES, D., PALMESINO, R. A., SHARIF, R., MCMARTIN, C., ERION, M. D., AND MILLER, M. J. S.: Rat vascular tissue contains a neutral endopeptidase capable of degrading atrial natriuretic peptide. J. Pharmacol. Exp. Ther. 251: 956-961, 1989.
567. TANG, J., YANG, H. Y. T., AND COSTA, E.: Inhibition of spontaneous and opiate-modified nociception by an endogenous neuropeptide with Phe-Met-Arg-Phe-NH2-like immunoreactivity. Proc. Natl. Acad. Sci. USA 81: 5002-5005, 1984.
568. TATEYAMA, H., HINO, J., MINAMINO, N., KANGAWA, K., OGIHARA, T., AND MATSUO, H.: Characterization of immunoreactive brain natriuretic peptide in human cardiac atrium. Biochem. Biophys. Res. Commun. 166: 1080-1087, 1990.
569. TEJEDOR-REAL, P., MICO, J. A., MALDONADO, R., ROQUES, B. P., AND GIBERT-RAHOLA, J.: Effects of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin degrading enzymes on a model of depression in the rat. Biol. Psychiatry, in press, 1993.
570. TERVO, K., TERVO, T., ERANKO, L., ERANKO, O., VALTONEN, S., AND CUELLO, C.: Effect of sensory and sympathetic denervation on substance P immunoreactivity in nerve fibers of the rabbit eye. Exp. Eye Res. 34: 577-585, 1982.
571. TERWILLIGER, R. Z., BEITNER-JOHNSON, D., SEVARINO, K. A., CRAIN, S. T., AND NESTLER, E. J.: A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res. 548: 100-110, 1991.
572. THAL, L. J., SHABPLESS, N. S., HIRSCHHOHN, I. D., HOROWITZ, S. G., AND MAKMAN, M. H.: Striatal met-enkephalin concentration increases following nigrostriatal denervation. Biochem. Pharmacol. 32: 3297-3301, 1983.
573. THORSETT, E. D., AND WYVRATT, M. J.: Inhibition of zinc peptidases that hydrolyse neuropeptides. In Neuropeptides and Their Peptidases, ed. by A. J. Turner, pp. 229-292, Horwood, Chichester, UK, 1987.
574. TOLLE, T. R., SCHADRACK, J., CASTRO-LOPES, J. M., EVAN, G., ROQUES, B. P., AND ZIEGLGANSBERGER, W.: Kelatorphan, naloxone and morphine differentially modulate the induction of immediate early genes in the spinal cord of the rat. Eur. J. Neurosci. 5 (Suppl.): 192, 1992.
575. TRAMPUS, M., ONGINI, E., VARANI, K., AND BOREA, P. A.: The neutral endopeptidase-24.11 inhibitor SCH 34826 does not change opioid binding but reduces D1 dopamine receptors in rat brain. Eur. J. Pharmacol. 194: 17-23, 1991.
576. TRAN-PATERSON, R., WILLARD, H. F., AND LETARTE, M.: The common acute lymphoblastic leukemia antigen (neutral endopeptidase-3.4.24.11) gene is located on human chromosome 3. Cancer Genet. Cytogenet. 42: 129-134, 1989.
577. TRAN-PATERSON, R., BOILEAU, G., GIGUERE, V., AND LETARTE, M.: Comparative levels of CALLA/neutral endopeptidase on normal granulocytes, leukemic cells, and transfected COS-1 cells. Blood 76: 775-792, 1990.
578. TRAPANI, A. J., SMITS, G. J., MCGRAW, D. E., SPEAR, K. L., KOEPKE, J. P., OLINS, G. M., AND BLAINE, E. H.: Thiorphan, an inhibitor of endopeptidase 24.11, potentiates the natriuretic activity of atrial natriuretic peptide. J. Cardiovasc. Pharmacol. 14: 419-424, 1989.
579. TURNER, A. J., HOOPER, N. M., AND KENNY, A. J.: Metabolism of neuropeptides. In Mammalian Ectoenzymes, ed. by A. J. Kenny and A. J. Turner, pp. 211-248, Elsevier Science Publisher, Amsterdam, The Netherlands, 1987.
580. UEDA, H., FUKUSHIMA, N., KITAO, T., GE, M., AND TAKAGI, H.: Low doses of naloxone produce analgesia in the mouse brain by blocking presynaptic autoinhibition of enkephalin release. Neurosci. Lett. 65: 247-252, 1986.
581. UKPONMWAN, O. E., POEL-HEISTERKAMP, A. L. V. D., AND DZOLJIC, M. R.: REM sleep deprivation decreases the grooming and shaking behaviour induced by enkephalinase inhibitor or opiate withdrawal. Pharmacol. Biochem. Behav. 23: 385-389, 1985.
582. UKPONMWAN, O. E., RUPRECHT, J., AND DZOLJIC, M. R.: An analgesic effect on enkephalinase inhibition is modulated by monoamine oxydase B and REM sleep deprivation., Naunyn Schmiedebergs Arch. Pharmacol. 332: 376-379, 1986.
583. UMEZAWA, S.: A new microbial metabolite phosphoramidon (isolation and structure). Tetrahedron Lett. 1: 97-100, 1972.
584. UMEZAWA, H., AOYAGI, T., TANAKE, T., SUDA, H., OKUYAMA, A., NAGANAWA, H., HAMADA, M., AND TAKEUCHI, T.: Production of actinin, inhibitor of aminopeptidase M, by actinomycetes. J. Antibiot. (Tokyo) 38: 1629-1630, 1985.
585. UNTERWALD, E. M., TEMPEL, A., KOOB, G. F., AND ZUKIN, R. S.: Characterization of opioid receptors in rat nucleus accumbens following mesolimbic dopaminergic lesions. Brain Res. 505: 111-118, 1989.
586. URA, N., CARRETERO, O. A., AND ERDÖS, E. G.: Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int. 32: 507-513, 1987.
587. VALET, P., BERLAN, M., BEAUVILLE, M., CRAMPES, F., MONTASTRUC, J. L., AND LAFONTAN, M.: Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein. J. Clin. Invest. 85: 291-295, 1990.
588. VALLEE, B. L., AND AULD, D. S.: Zinc coordination function and structure of zinc enzymes and others proteins. Biochemistry 29: 5647-5659, 1990.
589. VAN AMSTERDAM, J. G. C., VAN BUREN, K. J. M., BLOD, M. W. H., AND SOUJIKN, W.: Synthesis of enkephalinase B inhibitors, and their activity on isolated enkephalin-degrading enzymes. Eur. J. Pharmacol. 135: 411-418, 1987.
590. 5]-enkephalin levels and jump latency in mouse hot plate test. Eur. J. Pharmacol. 154: 319-324, 1988.
591. VAUGHT, J. L., AND CHIPKIN, R. E.: A characterization of kyotorphin (Tyr-Arg)-induced antinociception. Eur. J. Pharmacol. 79: 167-173, 1982.
592. VEMULAPALLI, S., CHIU, P. J., BROWN, A., GRISCTI, K., AND SYBERTZ, E. J.: The blood pressure and renal responses to SCH 34826, a neutral metallopeptidase inhibitor, and C-ANF (4-23) in DOCA-salt hypertensive rats. Life Sci. 49: 383-391, 1991.
593. VIDA, T. A., AND HERSH, L. B.: Glycosylation variants of endopeptidase-24.11 ("enkephalinase"). Neuropeptides 21: 245-255, 1992.
594. VIJAYARAGHAVAN, J., SCICLI, A. G., CARRETERO, O. A., SLAUGHTER, C., MOOMAW, C., AND HERSH, L. B.: The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J. Biol. Chem. 265: 14150-14155, 1990.
595. VILLANUEVA, L., CADDEN, S., CHITOUR, D., AND LE BARS, D.: Failure of ES52, a highly potent enkephalinase inhibitor, to affect nociceptive transmission by rat dorsal horn convergent neurones. Brain Res. 333: 156-160, 1985.
596. VILLARREAL, D., AND FREEMAN, R. H.: Captopril restores the renal responsiveness to synthetic atrial natriuretic factor in dogs with heart failure. Circulation 80: II-112, 1989.
597. VOGEL, Z., AND ALTSTEIN, M.: The adsorption of enkephalin to porous polystyrene beads: a simple assay for enkephalin hydrolyse. FEBS Lett. 80: 332-336, 1977.
598. VOGEL, Z., AND ALTSTEIN, M.: Degradation of enkephalin by two brain enzymatic activities. In Endogenous and Exogenous Opiate Agonists and Antagonist, ed. by E. L. Way, pp. 353-356, Pergamon Press, New York, 1979.
599. VOLLMAR, A. M.: Atrial natriuretic peptide in peripheral organs other than the heart. Klin. Wochenschr. 68: 699-708, 1990.
600. WAGNER, J. J., CAUDLE, R. M., NEUMAIER, J. F., AND CHAVKIN, C.: Stimulation of endogenous opioid release displaces mu receptor binding in the rat hippocampus. Neuroscience 37: 45-53, 1990.
601. WAGNER, J. J., EVANS, C. J., AND CHAVKIN, C.: Focal stimulation of the mossy fibers releases endogenous dynorphins that bind kappa, opioid receptors in the guinea pig hippocampus. J. Neurochem. 57: 333-343, 1991.
602. WAKSMAN, G., HAMEL, E., BOUBOUTOU, R., BESSELIEVRE, R., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Distribution regionale de l'enképhalinase dans le cerveau du rat par autoradiographie. C. R. Acad. Sci. Paris, series III 299: 613-616, 1984.
603. WAKSMAN, G., BOUBOUTOU, R., DEVIN, J., BOURGOIN, S., CESSELIN, F., HAMON, M., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: In vitro and in vivo effects of kelatorphan on enkephalin metabolism in rodent brain. Eur. J. Pharmacol. 117: 233-243, 1985a.
604. 3H]HACBO-Gly to the rat brain neutral endopeptides "enkephalinase." Biochem. Biophys. Res. Commun. 131: 262-268, 1985b.
605. WAKSMAN, G., HAMEL, E., FOURNIÉ-ZALUSKI, M. C., AND ROQUES, B. P.: Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of mu and delta opioid receptors in rat brain. Proc. Natl. Acad. Sci USA 83: 1523-1527, 1986a.
606. WAKSMAN, W., HAMEL, E., DELAY-GOYET, P., AND ROQUES, B. P.: Neuronal localization of the neutral endopeptidase "enkephalinase" in rat brain revealed by lesions and autoradiographie. EMBO J. 5: 3163-3166, 1986b.
607. WAKSMAN, G., HAMEL, E., DELAY-GOYET, P., AND ROQUES, B. P.: Neutral endopeptidase 24.11 mu and delta opioid receptors after selective brain lesions: an autoradiographic study. Brain Res. 436: 205-216, 1987.
608. WAKSMAN, G., LEMAY, G., ROQUES, B. P., CRINE, P., AND BOILEAU, G.: Deletions in the extracellular domain of neutral endopeptidase (EC 3.4.24.11) prevent both enzyme activity and transport to the cell surface. Eur. J. Biochem., in press, 1993.
609. WARNER, E. A., KRELL, R. D., AND BUCKNER, C. K.: Pharmacologic studies on the differential influence of inhibitors of neutral endopeptidase on nonadrenergic, noncholinergic contractile responses of the guinea pig isolated hilar bronchus to transmural electrical stimulation and exogenously applied tachykinins. J. Pharmacol. Exp. Ther. 254: 824-830, 1990.
610. WATKINS, L. R., KIMSCHECK, I. B., AND MAYER, D. J.: Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science 224: 395-396, 1984.
611. WEBB, R. L., YASAY, G. D., JR., MCMARTIN, C., MCNEAL, R. B., JR., AND ZIMMERMAN, M. B.: Degradation of atrial natriuretic peptide: pharmacologic effects of protease EC 24.11 inhibition. J. Cardiovasc. Pharmacol. 14: 285-293, 1989.
612. WERB, Z., AND CLARK, E. J.: Phorbol diesters regulate expression of the membrane neutral metalloendopeptidase (EC 3.4.24.11) in rabbit synovial fibroblasts and mammary epithelial cells. J. Biol. Chem. 264: 9111-9113, 1989.
613. WILCOX, J. N., POLLARD, H., MOREAU, J., SCHWARTZ, J. C., AND MALFROY, B.: Localization of enkephalinase mRNA in rat brain by in situ hybridization: comparison with immunohistochemical localization of the protein. Neuropeptides 14: 77-83, 1989.
614. WILLER, J. C., ROBY, A., AND ERNST, M.: The enkephalinase inhibitor GB52, does not affect nociceptive flexion reflexes nor pain sensation in humans. Neuropharmacology 25: 819-822, 1986.
615. WILKINS, M. R., RUTHERFORD, R. A. D., WHARTON, J., KIRK, J. E., AND POLAK, J. M.: Chronic inhibition of endopeptidase-24.11 reduces cardiac hypertrophy in experimental cardiac failure. Circulation 86 (Suppl. I): I-96, 1992.
616. WILLIAMS, J. T., CHRISTIE, M. J., NORTH, R. A., AND ROQUES, B. P.: Potentiation of enkephalin action by peptidase inhibitors in rat locus coeruleus in vitro. J. Pharmacol. Exp. Ther. 243: 397-401, 1987.
617. WILLIAMS, J. T., NORTH, R. A., AND TOKIMASA, T.: Inward rectification of resting and opiate-activated potassium currents in rat locus coeruleus neurons. J. Neurosci. 8: 4299-4306, 1988.
618. WISE, R. A., AND BOZARTH, M. A.: A psychomotor stimulant theory of addiction. Psychol. Rev. 94: 469-492, 1987.
619. WOOD, P. L.: Phasic enkephalinergic modulation of nigrostriatal dopamine metabolism: potentiation with enkephalinase inhibitors. Eur. J. Pharmacol. 82: 119-120, 1992.
620. WÜSTER, M., SCHULZ, R., AND HERZ, A.: Opioid tolerance and dependence: reevaluating the unitary hypothesis. Trends Pharmacol. Sci. 6: 64-67, 1985.
621. XIE, J., SOLEILHAC, J. M., RENWART, N., PEYROUX, J., ROQUES, B. P., AND FOURNIÉ-ZALUSKI, M. C.: Inhibitors of the enkephalin degrading enzymes: modulation of the activity of hydroxamate containing compounds by modification of the C-terminal residue. Int. J. Pept. Protein Res. 34: 246-255, 1989a.
622. XIE, J., SOLEILHAC, J. M., SCHMIDT, C., PEYROUX, J., ROQUES, B. P., AND FOURNIÉ-ZALUSKI, M. C.: New kelatorphan related inhibitors of enkephalin metabolism: improved antinociceptive properties. J. Med. Chem. 32: 1497-1503, 1989b.
623. XU, X. J., WIESENFELD-HALLIN, Z., HUGHES, J., HORWELL, D. C., AND HÖKFELT, T.: CI 988, a selective antagonist of cholecystokinin B receptors, prevents morphine tolerance in the rat. Br. J. Pharmacol. 105: 591-596, 1992.
624. 5]enkephalin levels and release in rat spinal cord. Eur. J. Pharmacol. 167: 367-373, 1989.
625. YAKSH, T. L., AND ELDE, R. P.: Factors governing release of methionine enkephalin-like immunoreactivity from mesencephalon and spinal cord of the cat in vivo. J. Neurophysiol. 46: 1056-1075, 1981.
626. 5-enkephalin. Eur. J. Pharmacol. 79: 293-300, 1982.
627. YAKSH, T. L., SABBE, M. B., LUCAS, D., MJANGER, E., AND CHIPKIN, R. E.: Effects of N-[L-(1-carboxy-2-phenyl)ethyl]-L-phenylalanyl-β-alanine (SCH 32615), a neutral endopeptidase (enkephalinase) inhibitor, on levels of enkephalin, encrypted enkephalins and substance P in cerebrospinal fluid and plasma of primates. J. Pharmacol. Exp. Ther. 256: 1033-1041, 1991.
628. YEAGER, C. L., ASHMUN, R. A., WILLIAMS, R. K., CARDELLICHIO, C. B., SHAPIRO, L. H., LOOK, A. T., AND HOLMES, K. V.: Human aminopeptidase N is a receptor for human coronavirus 229E. Nature (Lond.) 357: 420-422, 1992.
629. YOSHIMURA, M., AND NORTH, R. A.: Substantia gelatinosa neurones in vitro hyperpolarized by enkephalin. Nature (Lond.) 305: 529-530, 1983.
630. ZAJAC, J. M., CHARNAY, Y., SOLEILHAC, J. M., SALÈS, N., AND ROQUES, B. P.: Enkephalin-degrading enzymes and angiotensin-converting enzyme in human and rat meninges. FEBS Lett. 216: 118-122, 1987a.
631. ZAJAC, J. M., DELAY-GOYET, P., MESCHANSKI, M., SALÈS, N., CHARNAY, Y., GUILBAUD, G., AGID, Y., AND ROQUES, B. P.: Distribution in the brain and spinal cord (rat and human) of enkephalin targets (μ, δ) opioid receptors and enkephalinase) in various physiopathological conditions. In Protides of the Biological Fluids, Vol. 35, pp. 157-160, Pergamon Press, New York, 1987b.
632. ZAJAC, J. M., PESCHANSKI, M., BESSON, J. M., AND ROQUES, B. P.: High resolution autoradiography of opioid receptors and enkephalinase in the rat spinal cord. In Pain Research: Clinical Management, Vol. 3, ed. by R. Dubner, G. F. Gebhart, and M. R. Bond, pp. 436-441, Elsevier Science Publishers, New York, 1988.
633. ZAJAC, J. M., LOMBARD, M. C., PESCHANSKI, M., BESSON, J. M., AND ROQUES, B. P.: Autoradiographic study of μ and δ opioid binding sites and neutral endopeptidase 24-11 in rat after dorsal root rhizotomy. Brain Res. 477: 400-403, 1989.
634. ZHANG, A. Z., YANG, H. Y. T., AND COSTA, E.: Nociception, enkephalin content and dipeptidyl carboxypeptidase activity in brain of mice treated with exopeptidase inhibitors. Neuropharmacology 21: 625-630, 1982.
635. ZIGMOND, R. E., SCHWARZSCHILD, M. A., AND RITTENHOUSE, A. R.: Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annu. Rev. Neurosci. 12: 415-461, 1989.
636. ZUZEL, K. A., ROSE, C., AND SCHWARTZ, J. C.: Assessment of the role of enkephalinase in cholecystokinin inactivation. Neuroscience 15: 149-159, 1985.